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 As rates of overweight and obesity, and their related comorbid conditions continue to 
rise, the need to understand the mechanisms of obesity and metabolic disease and recommend 
strategies for prevention and treatment has never been greater. Dietary strategies for weight loss 
and weight maintenance offer the greatest opportunity to provide low-cost, safe, and universally 
available treatments compared to pharmaceutical and surgical interventions. Some dietary 
patterns, like the Mediterranean diet pattern, are widely known for their promotion of metabolic 
and whole-body health. However, a complete understanding of the mechanisms by which foods 
associated with the Mediterranean diet pattern contribute to health is lacking. The Mediterranean 
diet pattern is characterized by a high intake of fruits, vegetables, whole grains, legumes, and 
nuts; moderate consumption of seafood and red wine; and low consumption of the red and 
processed meats and sugar-sweetened beverages common in the Western diet pattern. Dietary 
fiber, a nutrient far more abundant in a Mediterranean diet pattern than a Western pattern, 
decreases inflammation through a complex web of physiological interactions including the 
modulation of the gastrointestinal (GI) microbiota and bacterial fermentation end-products, GI 
barrier structure and function, and the enterohepatic circulation of bile acids. 
One of the mechanisms by which consumption of dietary fibers may contribute to 
decreased whole-body inflammation is through the prevention of metabolic endotoxemia, 
defined as a 2- to 3- fold increase in the circulating concentrations of the pathogen associated 
molecular pattern lipopolysaccharide (LPS). As the largest reservoir of LPS in the body, the GI 
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CHAPTER 1: Microbiome-Mediated Effects of the Mediterranean Diet on Inflammation1 
 
Abstract 
The Mediterranean diet pattern is increasingly associated with improved metabolic health. Two 
mechanisms by which consuming a Mediterranean diet pattern may contribute to improved 
metabolic health are modulation of the gastrointestinal (GI) microbiota and reduction of 
metabolic endotoxemia. Metabolic endotoxemia, defined as a 2- to 3-fold increase in circulating 
concentrations of bacterial endotoxin, has been proposed as a cause of inflammation during 
metabolic dysfunction. As the largest source of endotoxins in the human body, the GI microbiota 
represents a crucial area for research on strategies for reducing endotoxemia. Diets high in 
saturated fat and low in fiber contribute to metabolic endotoxemia through several mechanisms, 
including changes in the GI microbiome and bacterial fermentation end products, intestinal 
physiology and barrier function, and enterohepatic circulation of bile acids. Thus, the 
Mediterranean diet pattern, rich in unsaturated fats and fiber, may be one dietary strategy to 
reduce metabolic endotoxemia. Preclinical studies have demonstrated the differential effects of 
dietary saturated and unsaturated fats on the microbiota and metabolic health, but human studies 
are lacking. The role of dietary fiber and the GI microbiome in metabolic endotoxemia is under 
investigated. Clinical research on the effects of different types of dietary fat and fiber on the GI 
microbiota and GI and systemic inflammation is necessary to determine efficacious dietary 
strategies for reducing metabolic endotoxemia, inflammation, and subsequent metabolic disease. 
 
1. The final, definitive version of this paper has been published in Advances in Nutrition 2018;9 
by the Oxford Press. © 2018 The Authors. Bailey MA, Holscher HD. Microbiome-Mediated 
Effects of the Mediterranean Diet on Inflammation. Adv Nutr. 2018;9:193-206. doi: 
https://doi.org/10.1093/advances/nmy013 
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1.1 Introduction  
Obesity rates continue to rise, with 35.0% of adult men and 40.4% of adult women 
affected in the United States (Flegal et al., 2016). Obesity-related morbidity represents a 
deepening crisis with diseases such as type 2 diabetes mellitus and cardiovascular disease 
afflicting 9.4%  (CDC, 2017) and 28.5% (Benjamin et al., 2017) of the US population, 
respectively, and contributing $209.7 billion in excess annual healthcare-associated costs 
(Spieker et al., 2016). Dietary strategies for the prevention and treatment of obesity and its 
comorbidities are an important research area. The Mediterranean diet pattern, characterized by 
high intake of fruits, vegetables, legumes, whole grains, and nuts; moderate consumption of 
seafood and red wine; and the use of olive oil as the main source of fat (Sofi et al., 2010) (Table 
1.1) is one dietary strategy recommended in the United States Department of Agriculture’s 2015-
2020 Dietary Guidelines for Americans as a way to promote health and prevent chronic disease 
(Department Health & Human Services, 2015). This is in comparison to the Western diet pattern, 
widely consumed in the US, which is characterized by high consumption of red and processed 
meats; high consumption of refined grains and sugar-sweetened beverages; and low consumption 
of fresh fruits, vegetables, and legumes (Bonaccio et al. 2012; Leon-Munoz et al., 2012; Castro-
Quezada, 2014) (Table 1.1). Epidemiological studies have revealed that consumption of a 
Mediterranean diet pattern is associated with lower all-cause mortality (hazard ratio (HR), 0.77; 
95% confidence interval (CI), 0.68-0.88) (Knoops et al.,2004), coronary heart disease (HR, 0.61; 
95% CI, 0.43-0.88) (Knoops et al.,2004), cardiovascular disease (HR, 0.71, 95% 0.58-0.88) (10), 
type 2 diabetes (HR, 0.84; 95% CI 0.62-1.14) (Brunner et al., 2008), and cancer (HR 0.81; 95% 
CI 1.28) (Brunner et al., 2008). However, clinical trials are limited (Table 1.2) and intervention 
trials often lack an explanation of the underlying mechanisms. 
 3 
Metabolic diseases, such as obesity (Cox et al., 2015; Scarpellini et al., 2004), type 2 
diabetes (Dandona, 2004; Duncan et al., 2003), cardiovascular disease (Rocha & Libby, 2009), 
and non-alcoholic fatty liver disease (Tilg & Moschen, 2008) are characterized by chronic 
subclinical inflammation with increased serum concentrations of pro-inflammatory cytokines 
like C-reactive protein (CRP), interleukin (IL)-6, and others. In an analysis of the 1988 to 1994 
National Health and Nutrition Examination Survey (NHANES), 20.2% of obese women had 
clinically elevated CRP concentrations (>1.0 mg/dl) compared to 4.0% of healthy weight women 
(Visser et al., 2017). In a case-cohort study, those in the highest quartile of serum IL-6 
concentrations (>2.96 pg/ml) had a 65% higher chance of developing diabetes compared to the 
lowest quartile (Duncan et al., 2003). Additionally, one prospective study reported that men in 
the highest tertile of serum CRP concentrations (>2.4 mg/l) had an odds ratio for coronary heart 
disease of 2.13 compared to those in the lowest tertile (<0.9 mg/l) after adjusting for known 
vascular risk factors (Danesh et al., 2000). The cause of this inflammation is a web of complex 
associations amongst diet, the gastrointestinal (GI) microbiome, and the immune system, which 
leads to a state of metabolic endotoxemia defined as a 2- to 3-fold increase in circulating 
concentrations of bacterial lipopolysaccharide (LPS) (Cani et al., 2007). Preclinical research 
provides evidence that microbial, immune, and dietary factors are collectively necessary for the 
development of metabolic endotoxemia as gnotobiotic mice (Caesar et al., 2012; Backhed et al., 
2007), mice with non-functional toll-like receptor (TLR) signaling pathways (Caesar et al., 
2015), and mice fed diets low in saturated fat (Caesar et al., 2015; Mani et al., 2013) do not 
exhibit the inflammation and metabolic disease that occurs when all these factors are combined.  
LPS, also known as endotoxins, are structures present on the outer membrane of gram-
negative bacteria, consisting of a polysaccharide O-antigen portion connected to a membrane-
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dwelling lipid-A portion. It is the lipid-A portion that exerts most of the immunogenic effects of 
LPS, including the activation of TLR4, an immune receptor that up-regulates the transcription of 
pro-inflammatory cytokines (Raetz & Whitfield, 2002). The O-antigen portion activates 
components of the adaptive immune system, which results in the production of antibodies. Both 
the lipid-A portion and O-antigen portion vary structurally and immunogenically (Reyes et al., 
2012), although this variation and its effects on metabolic endotoxemia are poorly understood. 
As the primary source of LPS in the body, changes in the composition of the GI microbiota 
and/or production of microbial metabolites may alter the pool of pathogen-associated molecular 
patterns that encounter the intestinal epithelium and enter circulation. Increasingly, diet has been 
shown to be the primary mediator of the composition and function of the GI microbiota 
(Sonnenburg & Backhed, 2016). Fat and fiber, two important components of the Mediterranean 
diet pattern, have differential effects on the GI microbiota. Diets high in saturated fat may 
exacerbate endotoxemia and inflammation by increasing transport of LPS (Mani et al., 2013), by 
increasing the amount of LPS available for transport by expanding the proportion of gram-
negative bacteria in the gut (Cani et al., 2007), or by the ability of saturated fats to stimulate 
TLR4 receptors directly (Lee et al., 2001; Shi et al., 2006). Conversely, high-fiber diets may 
decrease the proportion of gram-negative bacteria (Weickert & Pfeiffer, 2008) and improve gut 
barrier function, preventing endotoxemia (Wang et al., 2012) and subsequent metabolic disease. 
The aim of this review is to summarize the current state of knowledge about diet, the GI 
microbiome, and inflammation; elucidate gaps in knowledge; propose future areas of study; and 




1.2 Dietary Fatty Acids 
Staples of the Mediterranean diet pattern include nuts, seafood, and olive oil, which are 
rich in unsaturated fatty acids and low in saturated fatty acids. Consumption of these foods is 
lower than recommended for most age groups in the United States (Department Health and 
Human Services, 2015). This is problematic as overconsumption of saturated fats contributes to 
the development of cardiovascular disease (Astrup et al., 2011) and diabetes (Hu et al., 2001). 
The current average saturated fat intake in the US is 11% of energy, which exceeds the 
recommended limit set by the United States Department of Agriculture of 10%, and it is 
estimated that only 29% of the population meets this recommendation (Department Health and 
Human Services, 2015). In one clinical cross-over trial, participants consumed dietary patterns 
rich in saturated fatty acids or polyunsaturated fatty acids (PUFA) for 5 weeks each by 
substituting the respective fat sources, e.g., substituting butter with a PUFA-based spread and 
cooking oils and vice versa. At the end of the high PUFA and reduced saturated fat period, 
participants had a 20% increase in insulin sensitivity and a 19 mg/dl decrease in low-density 
lipoprotein-cholesterol (Summers et al., 2002). A systematic review of 102 clinical trials 
reported that replacement of saturated fat with PUFA resulted in decreased fasting glucose 
concentrations (0.04 mmol/L reduction), fasting insulin concentrations (0.5 pmol/L reduction), 
and insulin resistance (4% reduction) (Imamura et al., 2016). However, a meta-analysis of 8 
randomized controlled trials enrolling 663 participants reported that there was not strong 
evidence that replacement of dietary saturated fat with unsaturated fat improved blood lipid 




1.2.1 LPS translocation 
There are two main purported mechanisms by which bacterial LPS from the GI tract may 
enter systemic circulation: transcellularly, with the absorption of dietary fat, and paracellularly, 
through compromised enterocyte tight junctions (Lyte, 2016; Caesar et al., 2010). Preclinical 
studies have revealed that dietary fat absorption facilitates the translocation of LPS across the 
intestinal epithelium (Cani et al., 2007; Mani et al., 2013; Lagurette et al., 2012), and there is 
increasing evidence that these relationships also translate to clinical populations (Lyte, 2016; 
Erridge et al., 2007; Ghanim et al., 2009; Clemente-Postigo et al., 2012) (Table 1.3). During 
digestion, triglycerides, the predominant form of dietary fat, are broken down into free fatty 
acids that enter enterocytes by free diffusion through the cellular membrane and by specific fatty 
acid transporters (Kindel et al., 2010). These free fatty acids are then transported to the 
endoplasmic reticulum by fatty acid binding proteins where they are repackaged, along with 
cholesterol, fat-soluble vitamins, and LPS, into prechylomicrons (Kindel et al., 2010, Chen & 
Davidson, 2012). The prechylomicron, stabilized by apolipoprotein B, is transported through the 
Golgi apparatus, preparing it for secretion from the cell into lymphatic and eventually 
cardiovascular circulation (Chen & Davidson, 2012).  
While dietary lipids are absorbed mainly in the proximal small intestine, the majority of 
the GI microbiota, the largest source of LPS in the body, is resident in the distal small intestine 
and colon. One possible explanation for this contradiction is that endotoxemia may be the result 
of small intestinal bacterial overgrowth, which has been reported to be 17.1% more likely in 
those with obesity (Sabate et al., 2008). One clinical study of patients with non-alcoholic 
steatohepatitis reported that small intestinal bacterial overgrowth was present in 50% of 
participants. Intestinal permeability, plasma LPS concentrations (measured by Limulus 
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Amebocyte Lysate (LAL) assay), and serum tumor necrosis factor (TNF) concentrations were 
also measured. While intestinal permeability and plasma LPS concentrations were not 
significantly different between healthy patients and patients with non-alcoholic steatohepatitis, 
serum TNF concentrations were lower in healthy patients (14.2 pg/ml and 7.5 pg/ml, 
respectively) (Wigg et al., 2001). In another cross-sectional study, small intestinal bacterial 
overgrowth, defined as ≥ 105 total colony forming units/milliliter of jejunal secretions, was 
present in 59% of patients with liver cirrhosis. Endotoxemia (measured by LAL assay) was 
associated with small intestinal bacterial overgrowth, although no inflammatory markers were 
reported (Bauer et al., 2002). Taking these studies into account, measures of small intestinal 
bacterial overgrowth may be prudent additions to clinical studies of metabolic endotoxemia. 
The differential effects of dietary fats on metabolic endotoxemia has been investigated in 
several preclinical studies (Table 1.4).  One murine study compared mice fed diets supplemented 
with saturated fatty acids in the form of lard or unsaturated fatty acids in the form of fish oil. 
Circulating LPS concentrations (measured by LAL assay) were similar between groups at 3 
weeks of feeding but were higher in the lard-fed group at 11 weeks. Acutely, both saturated fat 
and unsaturated fat facilitate LPS translocation; however, chronically, metabolic endotoxemia 
was more pronounced in the high-saturated fat group, which may be due to long-term changes in 
the GI microbiota including an increase of Akkermansia muciniphila, which was only enriched in 
the fish oil-fed mice at 11 weeks (Caesar et al., 2015). In mice, Akkermansia is routinely reduced 
following periods of high-fat feeding and is inversely associated with obesity and inflammation 
(Schneeberger et al., 2015; Anhe et al., 2015),while reconstitution with A. muciniphila may 
improve insulin signaling and glucose tolerance (Everard et al., 2013). 
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Other murine studies that compare the immunomodulatory effects of dietary fat types 
have similarly demonstrated the deleterious effects of diets high in saturated fats. Mice fed a 
high-monounsaturated fatty acid (MUFA; canola oil) diet or a high-saturated fat (palm oil) diet 
had higher plasma LPS concentrations (measured by LAL assay) in the canola oil condition, but 
higher plasma concentrations of the pro-inflammatory cytokines IL-6 and IL-1b in the palm oil 
condition. In an accompanying in vitro experiment, adipocytes stimulated with LPS and 
incubated with palm oil had higher expression of the endotoxin-sensing TLR4 and cluster of 
differentiation (CD) 14 compared to adipocytes incubated with canola oil (high n-3 PUFA), 
sunflower oil (high n-6 PUFA), or milk fat (high saturated fat) (Table 1.5). This suggests that 
while both high saturated and unsaturated fats may induce endotoxemia, high saturated fat diets 
generally lead to more inflammation than unsaturated fats in mice (Laugerette et al., 2012). 
The differential effects of postprandial saturated and unsaturated fat exposure on gut 
permeability and endotoxemia were further demonstrated in a porcine model, whereby 
postprandial serum LPS concentrations (measured by PyroGene™ rFC Assay, Lonza™, 
Switzerland) were increased with saturated fat (coconut oil) consumption as compared to n-3 
PUFAs (fish oil). Additionally, ex vivo treatment of ileal epithelium with fish oil and cod liver oil 
reduced gut permeability, while treatment with coconut oil increased permeability. The authors 
attributed this increase in permeability to the tendency of saturated fats to form lipid rafts in the 
cellular membranes of enterocytes, thereby decreasing membrane fluidity. Saturated fat-induced 
endotoxemia was attenuated by administration of a compound that causes dissociation of lipid 
rafts (Mani et al., 2013). This preclinical evidence (Caesar et al., 2015; Mani et al., 2013; 
Laugerette et al., 2012) demonstrates how diets high in saturated fat may induce metabolic 
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endotoxemia and systemic inflammation through increasing intestinal permeability and altering 
the GI microbiota composition. 
 
1.2.2 Fat and the GI microbiota 
Diets high in saturated fat may alter the GI microbiome and intestinal physiology in ways 
that contribute to metabolic dysfunction. Using a murine model, one study demonstrated that a 
high-fat (45% energy) palm oil diet decreased fat absorption and increased fecal fat 
concentrations compared to a high-fat olive oil or high-fat safflower oil diet, with the three 
groups presenting daily fecal fat concentrations of 27.7 mg/day, 16.8 mg/day, and 17.6 mg/day 
for the palm oil, olive oil, and safflower groups, respectively. Increased fecal fat concentrations 
in the palm oil group were accompanied by a reduction in microbial diversity, increased 
Firmicutes-to-Bacteroidetes ratio, and an increase in mucosal expression of lipid-related genes. 
The authors hypothesized that the presence of higher amounts of fatty acids in the distal intestine 
had an antimicrobial effect that produced a loss of overall diversity (de Wit et al., 2012), 
considered to be a sign of dysbiosis.   
Another murine study demonstrated the deleterious effects of an exceptionally high fat 
diet (72% energy) reporting an increased proportion of gram-negative gut microbes, a 2- to 3-
fold increase in circulating concentrations of LPS; increased liver, adipose, and skeletal muscle 
expression of pro-inflammatory cytokines (TNF, IL-1, IL-6, and plasminogen activator 
inhibitor); poorer glucose tolerance; and increased hepatic triglyceride. Interestingly, mice 
deficient in the LPS receptor protein, CD14, were spared the negative effects of the high-fat diet, 
exhibiting hypersensitivity to insulin and normal liver triglyceride content, suggesting the 
LPS/CD14 system was driving the metabolic effects of the high-fat diet in the wild-type mice 
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(Cani et al., 2007). While these two preclinical studies utilized diets higher in fat (45% and 72% 
of energy for these two studies, respectively) than the American average of 35% (USDA, 2016), 
they draw attention to the need for further clinical investigation of dietary fats, the GI 
microbiota, and endotoxemia.  
Fat and fiber have differential effects on the GI microbiome. Pre-clinical research has 
demonstrated that high-fat feeding may increase the proportion of gram-negative bacteria in the 
gut while decreasing the abundance of some gram-positive bacteria like the Eubacterium rectale-
Clostridium coccoides group and Bifidobacterium (Cani et al., 2012). This may be because gram-
negative bacteria are generally more bile-tolerant than gram-positive bacteria for reasons that are 
still poorly understood, but may include the protective qualities of LPS (Begley et al., 2005), as 
bacteria lacking the O-antigen portion of the LPS structure have reduced bile acid-tolerance 
(Otte & Podolsky, 2004). However, not all gram-positive bacteria respond poorly to a fat 
challenge and some gram-negative bacteria flourish during high-fiber feeding. For example, the 
gram-negative genera Prevotella is fiber-degrading and enriched in high-fiber diets (De Filippo 
et al., 2010), while the gram-positive Clostridia class are bile resistant and increased during high-
fat feeding (Ridlon et al., 2014). Additionally, a cross-sectional study of children consuming a 
traditional rural African diet in Burkina Faso compared to children consuming a Western diet in 
Italy revealed that children from Burkina Faso had greater (58.5%) abundance of gram-negative 
bacteria, particularly Bacteroidetes, while European children had greater (70.4%) abundance of 
gram-positive bacteria, particularly Firmicutes. The diets of these two groups varied greatly with 
the African children consuming more fiber and fewer calories (1-2 years of age: 10 g fiber, 672.2 
kcal; 2-6 years of age: 14.2 g fiber, 996 kcal) than the European children (1-2 years of age: 5.6 g 
fiber, 1068.7 kcal; 2-6 years of age: 8.4 g fiber, 1512.7 kcal) (De Filippo et al., 2010). Clinical 
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studies utilizing complete feeding interventions have demonstrated that the addition of walnuts 
or almonds (high in unsaturated fats and fiber) to the diet facilitates increases in several genera of 
gram-positive bacteria in the Clostridia class including Lachnospira, Roseburia, Oscillospira 
(Holscher et al., 2018) Faecalibacterium, and Clostridium (Holscher et al., 2018), and decreases 
in others, including Ruminococcus, Dorea, and Bifidobacterium (member of class 
Actinobacteria) (Holscher et al., 2018). 
One reason a simple gram-negative/gram-positive divide may not be possible is the 
variation in immunogenicity of LPS between species of gram-negative bacteria, so that it may 
not be the abundance of gram-negative bacteria that predicts inflammation, but rather the 
abundance of highly immunogenic LPS-producing gram-negative bacteria. It has been 
demonstrated that GI microbial dysbiosis can result in inappropriate immune activity. One study 
comparing type 1 diabetes incidence and differences in microbiome structure in children reported 
a high abundance of Bacteroides and low abundance of E. coli in children from Finland and 
Estonia, where type 1 diabetes rates are high, and a high abundance of E. coli and low abundance 
of Bacteroides in children from Russia, where type 1 diabetes rates are low. The authors further 
demonstrated that differences in the LPS structure between the Bacteroides species and E. coli 
may account for the improper education of the immune system in children with type 1 diabetes 
(Vatanen et al., 2016). These results were complemented by a study that demonstrated that mice 
with non-functional TLR4 pathways do not develop type 1 diabetes, further implicating the LPS-
TLR4 system in inappropriate immune education (Wen et al., 2008). This type of work has not 
been replicated for metabolic endotoxemia in adults, but would be of great value in the 
elucidation of the mechanisms by which microbiome structure affects inflammation and 
metabolic disease. 
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1.2.3 Endotoxemia and Inflammatory Markers 
Clinical studies of metabolic endotoxemia often use a method of LPS quantification 
called the Limulus Amebocyte Lysate assay (Table 1.3). The LAL is an extract of blood cells 
from the North American horseshoe crab, which coagulates when in contact with LPS. However, 
this reagent cannot be used for LPS detection in human blood due to proteins and other factors in 
human blood which interfere with the enzymatic cascade that results in LAL coagulation 
(Novitsky, 1998). Indeed, the LAL assay fails to provide specific, sensitive, and reproducible 
results for the quantification of endotoxin in human blood, plasma, and sera samples (Novitsky, 
1998). To improve reproducibility, some have introduced a method which involves diluting and 
heating the plasma or sera samples before the introduction of the LAL, which denatures the 
interfering proteins (Gnauck et al., 2015). Although this does improve reproducibility, this 
method fails to produce results that are reflective of the total amount of circulating LPS (Gnauck 
et al., 2015).  
As plasma LPS is difficult to measure by direct assay, indirect methods may be more 
accurate, such as LPS-binding protein assay (Opal et al., 1999), or proxy measures of 
endotoxemia like inflammatory cytokines (IL-6, TNF, and CRP). A comparison of two clinical 
trials assessing LPS and other inflammatory cytokines exemplifies the inconsistencies among 
measures.  One clinical study of the effects of a high-fat meal (~900 kcal serving of toast with 
butter) on endotoxemia reported a 50% increase in circulating endotoxin concentrations 
compared to baseline (measured by LAL assay) (Erridge et al., 2007). However, neither plasma 
CRP nor TNF concentrations were increased after the high-fat challenge (Erridge et al., 2007). In 
another clinical trial, participants given a high-fat, high-carbohydrate meal (egg muffin and 
sausage muffin sandwiches and two hash browns) had a 47% increase in plasma LPS 
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concentrations (measured by LAL assay) 3 hours postprandially compared to baseline. This 
increase in LPS was accompanied by a 72% increase in DNA binding by nuclear factor kappa-
light-chain-enhancer of activated B cells (NFkB), a transcription factor which upregulates the 
expression of pro-inflammatory cytokines, in mononuclear cells over baseline, as well as 
increased expression of TLR2 and TLR4 in these cells (Ghanim et al., 2009). These additional 
inflammatory measures provide valuable insight into the physiologic postprandial state that is not 
possible with LPS measurements alone.  
 
1.2.4 Bile acids 
Bile acids are another mechanism by which dietary fats and fibers impact the GI 
microbiota and intestinal physiology. Bile acids are increasingly implicated in the pathogenesis 
of human colitis and colorectal cancer and this may be due to their interactions with the 
microbiome and immune system (Ajouz et al., 2014). Exposure to secondary bile acids alters 
gene expression in enterocytes and microbiota. Cholic acid and chenodeoxycholic acid, the 
primary bile acids produced in the human liver (Mayi et al., 2012), are deconjugated and 
dehydroxylated by gut bacteria to produce the secondary bile acids deoxycholic acid and 
lithocholic acid (Nagengast et al., 1995), which have both been associated with localized gut 
inflammation in mice (Klimesova et al., 2013). Elevated concentrations of deoxycholic acid in 
the serum and feces have been reported in humans with colon cancer (Schwabe & Jobin, 2013) 
and in murine studies, deoxycholic acid exposure modifies the expression of genes involved in 
inflammation, apoptosis, cell proliferation, DNA repair, and angiogenesis (Bernstein et al., 
2011). Increased fecal concentrations of deoxycholic acid were also associated with disruption of 
gut barrier function in mice at physiologic concentrations associated with a high-fat diet, while 
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low-fat diet-related concentrations do not affect barrier function (Stenman et al., 2013). 
Furthermore, mice fed deoxycholic acid had a 1.5-fold increase in intestinal permeability 
compared to control mice. High-fat diets are also associated with decreased fecal concentrations 
of ursodeoxycholic acid, which may be cytoprotective as this decrease in fecal excretion is also 
associated with a disruption in barrier function in mice (Stenman et al., 2013).  
Changes in the intestinal bile acid pool during periods of high saturated fat intake may 
alter the microbiome composition and increase intestinal inflammation. One murine study 
investigating the effects of dietary fat saturation on bile acids and the gut microbiota reported a 
bloom in the sulfite-reducing bacterium Bilophila wadsworthia, a pathobiont not normally 
abundant in healthy individuals, and the development of colitis in genetically susceptible mice 
during a high-saturated fat diet. After feeding mice a diet with 37% of energy from fat in the 
form of milk fat, lard, safflower oil, or a low-fat diet, the milk fat group exhibited an expansion 
of B. wadsworthia, which the authors attribute to an increase in bioavailable sulfur in the form of 
taurine-conjugated bile acids. This effect was reported to be a direct effect of the dietary milk fat. 
The increase in sulfur-containing bile acids was not found in the lard, safflower, or low-fat 
groups, but was replicated in a low-fat group with taurocholic acid supplementation (Devkota et 
al., 2012). A strength of this study is that the composition of this diet (37% of energy from fat, 
including 15% from saturated fat) is similar to the Western diet (35% of energy from fat, 
including 11% from saturated fat) (USDA, 2016).    
Bile acids have profound effects on the structure of the microbial community in the GI 
tract, both stimulating the growth of microbes that utilize bile as an energy source and repressing 
the growth of microbes that are intolerant to its detergent effects (Ridlon et al., 2014). Increased 
concentrations of bile acids, which may result from a high-fat diet, favor the expansion of gram-
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positive members of the Firmicutes phylum, including some members of the Clostridia class 
capable of secondary bile acid production like Blautia and Rumminococcaceae (Ridlon et al., 
2014). Secondary bile acid production allows certain microbes to decrease competition for 
nutrients because these bile acids act as electron carriers for cellular metabolism and as 
antimicrobial agents (Ridlon et al., 2014). In a murine model, the addition of cholic acid to the 
diet increased the Firmicutes/Bacteroides ratio, decreased bacterial diversity, and increased 
deoxycholic acid production (Islam et al., 2011). The authors noted that dietary cholic acid 
mimicked the effects of a high-fat diet and also resulted in a decrease in serum adiponectin 
concentrations (Islam et al., 2011), which is associated with obesity and its related comorbidities 
(Ukkola & Santaniemi, 2002). 
 
1.3 Dietary Fiber 
 Much like dietary fats, dietary fibers are a highly heterogeneous group of molecules that 
vary in solubility (the ability to dissolve in aqueous solutions), viscosity (the ability to form gels 
in aqueous solutions), and fermentability (the ability to be anaerobically metabolized by GI 
microbes) (McRorie & Fahey, 2013). Using these three characteristics, dietary fiber can be 
divided into 4 clinically-significant designations: insoluble; soluble, non-viscous, and readily 
fermentable; soluble, viscous, and readily fermentable; and soluble, viscous, and non-
fermentable (McRorie & Fahey, 2013). Other recent reviews provide additional insight on the 
differential effects of these 4 designations of fiber on the structure and function of the GI 
microbiota  (Holscher, 2017) and clinical implications of fiber ingestion (McRorie & Fahey, 
2013). 
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Americans fall short of the 14 g fiber per 1,000 kilocalorie recommendation with the 
average adult consuming only 8 g of fiber per 1,000 kilocalories per day (USDA, 2016). The 
current level of intake is related to deficits in the consumption of legumes, whole grains, fruits, 
and vegetables (Department Health and Human Services, 2015). Indeed, the majority of fiber in 
the US diet is from foods made of refined grains, which have up to 80% of the fiber removed 
during processing (Department Health and Human Services, 2015). The Mediterranean diet 
pattern, abundant in plant foods, may be one way of increasing fiber intake. In a 2-year 
randomized controlled trial, those following a Mediterranean diet pattern increased fiber intake 
by 18 g/day—at baseline, participants were consuming 14 ± 1.2 g/day, which mirrors the average 
intake in the US, while at the 2-year time point, participants were consuming an average of 32 ± 
2.8 g/day (Esposito et al., 2004). Evidence supporting the health benefits of a high-fiber diet is 
abundant and continues to grow with one review comparing metabolic disease risk in high vs. 
low fiber consumers reporting reductions in the relative risk of developing obesity (30%), 
coronary artery disease (29%), and diabetes (18%)(Anderson et al., 2009). Additionally, a recent 
meta-analysis of 12 randomized controlled trials, including 609 adult participants with 
overweight and obesity, reported that isolated soluble fiber intake reduced BMI by 0.84 kg/m2, 
body weight by 2.52 kg, body fat by 0.41%, fasting glucose by 0.17 mmol/L, and fasting insulin 
by 15.88 pg/ml compared with the effects of placebo treatments (Thompson et al., 2017). 
 
1.3.1 Fiber and the GI Microbiota 
Knowledge of the associations between the GI microbiota and health has expanded 
greatly in recent decades. It is now known that altered microbiota composition is associated with 
many disease states including obesity, nonalcoholic fatty liver disease, and inflammatory bowel 
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disease (Cho & Blaser, 2012). Diet, and dietary fiber especially, has a profound impact on the GI 
microbiota. Fiber-rich, plant-based diets have been associated with greater microbial richness 
both in taxonomy and gene expression (De Filippis et al., 2016). Richness is a marker of 
microbial community health and perhaps host health as well. Low microbial richness has been 
associated with greater adiposity, insulin resistance, dyslipidemia, and inflammation (Le 
Chatelier et al., 2013). 
 Humans rely on microbes to metabolize the indigestible components of food like dietary 
fibers (Ley et al., 2006). Short-chain fatty acids (SCFA) are the end-products of microbial fiber 
fermentation and our understanding of their effects on human health is still unfolding. An 
observational study of high-level adherence to a Mediterranean diet pattern found significant 
associations between plant-based diets and microbiome structure and function (De Filippis et al., 
2016). Those consuming vegetarian and vegan diets had enriched fiber-degrading bacteria 
Prevotella and Lachnospira, compared to those following an omnivorous diet. Additionally, 
SCFA concentrations were positively correlated with adherence to the Mediterranean diet pattern 
regardless of diet-type. The authors also reported that those with high animal protein and fat 
intake had higher urinary concentrations of phenolic and indolic compounds derived from the 
deamination of aromatic amino acids and methylamines by the GI microbiota. Of specific 
concern is the microbial-derived compound trimethylamine oxide, which has been linked to the 
development of atherosclerosis (De Filippis et al., 2016). 
Fecal SCFA concentrations are indicative of intestinal health and are an important 
measure in clinical research where more direct sampling of the intestinal environment is not 
always feasible. The most abundant fecal SCFA is acetate (40-70 mM), followed by propionate 
and butyrate (10-30 mM). SCFA are readily absorbed from the intestinal lumen into circulation 
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with acetate reaching the highest concentration in serum of the three. Acetate is mainly utilized 
by peripheral tissues, propionate by the liver, and butyrate by the colonic mucosal cells (Russell 
et al., 2013). In one study of the effects of butyrate on colonic gene expression, healthy adult 
volunteers received enemas containing butyrate in concentrations achievable through a high-fiber 
diet or a placebo enema containing no butyrate. Analysis of human colon tissue biopsies revealed 
an increase in expression of genes involved in energy metabolism, fatty acid metabolism, and 
oxidative stress in the butyrate group. Additionally, butyrate was shown to differentially regulate 
genes involved in gut integrity and apoptosis (Vanhoutvin et al., 2009), which may be one 
mechanism by which butyrate decreases gut inflammation. Indeed, colonic expression of NFkB 
inhibitor a, an inhibitor of the pro-inflammatory transcription factor NFkB, was upregulated in 
the butyrate group (Vanhoutvin et al., 2009). 
Butyrogenic bacteria and bacteria that cross-feed with butyrogenic bacteria are common 
targets of prebiotic fiber interventions. Cross-feeding occurs when one species produces 
substrates that are utilized by another species. For example, two molecules of acetate can be 
converted into butyrate via microbes that possess the enzyme butyryl-CoA (Riviere et al., 2016). 
Bifidobacterium is a main GI symbiont of interest because of its interaction with the innate 
immune system and production of acetate and lactate, which has been shown in vitro to be a 
substrate for cross-feeding with butyrogenic species like Faecalibacterium prausnitzii, 
Anaerostipes spp., Eubacterium spp., and Roseburia spp. that possess the butyryl-CoA enzyme 
(Riviere et al., 2016). In vivo, a study in healthy adults consuming up to 7.5 grams of agave 
inulin per day reported a bloom in Bifidobacterium and a positive correlation between increasing 
dietary fiber and butyrate concentration, as well as positive relations between Faecalibacterium 
and butyrate concentrations. As Faecalibacterium possess the butyryl-CoA enzyme, the authors 
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purported that these relations between butyrate and increasing dietary fiber may be in part related 
to the increased Bifidobacterium that resulted from inulin consumption (Holscher et al., 2015). 
Indeed, in vivo studies of prebiotic supplementation which report an increase in Lactobacillus 
and/or Bifidobacterium and butyrate, cross-feeding is likely the mechanism responsible for an 
increase in butyrate as neither Lactobacillus nor Bifidobacterium are capable of producing 
butyrate.  
 
1.3.2 LPS translocation 
Dietary fibers are the second nutrient of greatest interest in preventing metabolic 
endotoxemia due to their ability to block both transcellular and paracellular routes of LPS 
translocation. As stated above, dietary fiber can be divided into four clinically significant 
classifications described by McRorie and Fahey 2013. Those fibers that are soluble and viscous 
like pectin, b-glucan, and psyllium, reduce lipid digestion, which may also contribute to reduced 
transcellular translocation of LPS. Pectins specifically have been shown to interact with bile 
acids and phospholipids, reducing the amount of surface-active components, and reducing the 
solubility of dietary fats (Espinal-Ruiz et al., 2014). Another study investigating the effects of 
cereal fiber on fecal composition reported an increase in fecal fat concentrations when dietary 
fiber consumption was increased from 17 g/day to 45 g/day (Cummings et al., 1976). This 
reduced fat absorption may also lead to reduced LPS translocation. 
Through interactions with the GI microbiota, the presence of fermentable dietary fibers in 
the diet may strengthen gut barrier function, thus preventing paracellular translocation of LPS. In 
a study of fermentable vs non-fermentable fiber supplementation on a high-fat diet, mice fed 
10% short-chain fructooligosaccharide or 10% inulin fiber (both fermentable fibers) had greater 
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cecal crypt depth (short-chain fructooligosaccharide 141µm; inulin: 145µm) than mice fed 
cellulose (non-fermentable fiber) (5% and 10%: 109µm). Additionally, inulin-fed mice had 
greater cecal transmural resistance (101 W X cm2) than 5% cellulose-fed mice (45 W X cm2) 
(90). Butyrate has been shown to upregulate the expression of tight junction proteins and 
increase the rate of tight junction assembly, buttressing gut barrier integrity. An in vitro study of 
rat intestinal cells found that butyrate increases the expression of tight junction Claudin-1, an 
important component of barrier function (Wang et al., 2012). Similarly, an in vitro study of 
human colonic epithelial cells showed that butyrate also increases the activity of adenosine 
monophosphate-activated protein kinase, increasing the rate of tight junction assembly (Peng et 
al., 2009). This type of mechanistic research can be difficult to replicate in humans, but an 
increasing number of clinical studies investigate fecal SCFA concentrations. A recent systematic 
review and meta-analysis of 68 clinical studies of SCFA and systemic inflammation reported a 
significant decrease in ³ 1 marker of systemic inflammation (CRP, TNF, IL-6) in 14 of the 29 
included prebiotic studies and 13 of the 26 synbiotic studies and this association was stronger in 
studies that supplemented oligosaccharides. The meta-analyses revealed a reduction in CRP with 
prebiotic consumption and a reduction in CRP and TNF with synbiotic consumption although 
there was a high degree of heterogeneity amongst the included studies indicating a need for 
further research (McLoughlin et al., 2017). In a study measuring high-level adherence to the 
Mediterranean diet pattern, those with the greatest level of adherence to the diet pattern had the 
highest fecal SCFA concentrations (De Filippis et al., 2016).; however, no measures of 
endotoxemia or inflammation were collected.  
Using a murine model, one preclinical trial demonstrated the effects of prebiotic 
(arabinoxylan oligosaccharide) supplementation on metabolic endotoxemia and inflammation. 
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Obese mice fed a high-fat (60% of energy) diet supplemented with 7.5% (w/w) arabinoxylan 
extract exhibited less fat mass development, better insulin sensitivity, upregulation of intestinal 
tight junction proteins, lower plasma endotoxin concentrations (measured by LAL assay), and 
significantly lower circulating concentrations of IL-6 than mice fed the same high-fat diet 
without arabinoxylan supplementation (Neyrinck et al., 2012). These improvements in metabolic 
health and measures of metabolic endotoxemia may be explained by changes in the GI 
microbiota. Arabinoxylan supplementation resulted in a 2-log increase in cecal Bifidobacterium, 
cecal and colon enlargement, and an increase in colonic expression of genes related to SCFA 
response (Neyrinck et al., 2012).  This thorough experiment, which provides measures of GI 
microbial structure, gut integrity, circulating LPS, and inflammation creates a detailed picture of 
how diet-induced changes in the microbiome affect the translocation of LPS and development of 
endotoxemia. 
 
1.3.3 Inflammation and metabolic disease 
A reduction in endotoxemia and inflammation may be one mechanism by which 
increased consumption of dietary fiber improves metabolic health. An analysis of data from the 
1999-2000 NHANES, reported an inverse relationship between dietary fiber intake and the risk 
of having elevated CRP, defined by the American Heart Association as a serum concentration 
greater than 3.0 mg/l, and a modest direct association of saturated dietary fat intake and the risk 
of elevated serum CRP, a potent pro-inflammatory cytokine (King et al., 2003). The protective 
effects of dietary fiber were seen in the 3rd and 4th highest quartiles of intake defined as 
consuming 13.3-19.5 g/day and >19.5 g/day respectively, which both fall short of the 28 g/day 
suggested by the 2015-2020 Dietary Guidelines for Americans (Department Health and Human 
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Services, 2015). Those in the highest quartile of saturated fat intake were consuming greater than 
35.1 g/day (King et al., 2003). Although these analyses are almost two decades old, this study 
maintains its relevance as fiber consumption has remained similar from 1999-2014. Median fiber 
consumption reported in 1999-2000 NHANES data was 6.5 g/1,000 kcals and 8 g/1,000 kcals in 
the 2013-2014 NHANES data. This is one illustration of the pro-inflammatory effects of 
saturated fat and anti-inflammatory effects of dietary fiber. However, when the effects of a 
Mediterranean diet pattern were tested clinically in a cohort of healthy male university students 
there was no change in CRP concentrations (Mezzano et al., 2001), which may be due to the 
difficulty of measuring CRP in healthy individuals (King et al., 2003). . 
A recent large prospective single-center cohort study examined the relationship between 
consumption of a Mediterranean diet pattern and endotoxemia—the authors reported that plasma 
LPS concentrations (measured by enzyme-linked immunosorbent assay (ELISA)) were 
negatively associated with adherence to the Mediterranean diet pattern (measured by validated 
questionnaire) and with fruit and legume intake in adults with atrial fibrillation (Pastori et al., 
2017). Plasma LPS concentrations were also positively associated with plasma low-density 
lipoprotein-cholesterol and major adverse cardiovascular events (Pastori et al., 2017). This study 
provides a valuable report on the links between consumption of a Mediterranean diet pattern and 
improved cardiometabolic health through decreased metabolic endotoxemia. However, 
interventional trials in a more general population should be conducted to determine if these links 
are causative. It should also be noted that use of ELISA for the quantification of plasma LPS 
concentrations is regarded with similar skepticism as the LAL assay (Munford, 2016). 
Unfortunately, no other inflammatory measures were reported in this paper. 
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Short-chain fatty acids and particularly butyrate have further immunoregulatory effects 
and are increasingly recognized for their ability to disrupt the development and progression of 
metabolic disease. SCFAs have a profound ability to regulate the activity of leukocytes including 
recruitment to sites of inflammation and the production of cytokines like TNF, IL-2, IL-6, and 
IL-10, eicosanoids, and chemokines (Vinolo et al., 2011). In vitro, butyrate appears to have a 
greater influence on leukocyte behavior than acetate or propionate and an overall anti-
inflammatory effect (Cavaglieri et al., 2003). This may be one mechanism by which butyrate 
prevents the development of metabolic dysfunction. One murine study demonstrated the ability 
of butyrate to prevent insulin resistance in obese mice fed a high-fat diet supplemented with 5% 
wt/wt butyrate (Gao et al., 2009). Another set of murine studies has demonstrated that 
supplementation of sodium butyrate  (Jin et al., 2015) and a butyrate-producing probiotic, 
Clostridium butyricum (Endo et al., 2013), hinder the progression of non-alcoholic fatty liver 
disease to non-alcoholic steatohepatitis.  
There have been many clinical trials that have investigated the effects of a Mediterranean 
diet pattern on metabolic syndrome and one meta-analysis reporting on 8 studies with over 
10,000 participants, found 5 studies which reported a beneficial effect of a Mediterranean diet 
pattern. Some of these benefits included reduced waist circumference (-0.42 cm), increased 
serum high-density lipoprotein-cholesterol (1.17 mg/dl), decreased serum triglycerides (-6.14 
mg/dl), decreased systolic (-2.35 mmHg) and diastolic (-1.58 mmHg) blood pressure, and 
decreased blood glucose (-3.89 mg/dl) in participants instructed to consume a Mediterranean diet 
pattern compared to those who were not given instructions to change their diet (Kastorini et al., 
2011). Although it has been demonstrated that a Mediterranean diet pattern can improve 
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 In addition to dietary fiber, high consumption of whole plant foods as part of the 
Mediterranean diet pattern provides an abundance of phytochemicals that also affect the GI 
microbiome, inflammation, and the development of metabolic disease. Phytochemicals, which 
include polyphenols, phenolic acids, flavonoids, carotenoids, and lignans (Visioli et al., 2000; 
Saura-Calixto & Goni, 2006) are not defined as essential nutrients but have been shown to 
decrease the risk of coronary heart disease (Visioli et al., 2000; Arai et al., 2000), diabetes (Xiao 
& Hogger, 2015), and non-alcoholic fatty liver disease (Rodriguez-Ramiro et al., 2016). This 
reduction in risk may be due to interactions with the GI microbiome and immune system. 
Phytochemicals that escape absorption in the proximal small intestine may be transformed by the 
microbiota in the distal small intestine, increasing phytonutrient availability and altering the 
structure of the microbial community (Cardona et al., 2013; Laparra & Sanz, 2010). One in vitro 
study of the effects of phenolic compounds in tea reported repression of pathogenic microbes 
such as Clostridium perfringens, Clostridium difficile, and Bacteroides spp. without significantly 
affecting concentrations of commensal microbes such as Clostridium spp., Bifidobacterium spp., 
and Lactobacillus spp. (Lee et al., 2006). Proanthocyanidins have a similar effect on the 
microbiome, stimulating the growth of Lactobacillus spp., Bifidobacterium spp., and some 
butyrate-producing bacteria while decreasing colonic inflammation (Cires et al., 2017).  
Preclinical trials have demonstrated the ability of polyphenols to improve gut barrier 
function in mice (Gu et al., 2014), ameliorate metabolic endotoxemia in mice and rats (Gu et al., 
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2014; Yuan et al., 2006), prevent LPS-induced liver damage on a high-fat diet in rats (Yuan et 
al., 2006) and aid in the prevention of type 2 diabetes in humans (Gausch-Ferre et al., 2017). One 
clinical trial in which participants were given a meal with grape extract or a placebo reported 
lower postprandial endotoxemia (measured by LAL assay) in the grape extract group (Wong et 
al., 2016). Unfortunately, the Western diet pattern, which is characterized by low consumption of 
fruits, vegetables, legumes and whole grains provides a dearth of phytochemicals. There is a 
large gap between the 2 cup-equivalents per day of fruits and 2.5 cup-equivalents per day of 
vegetables recommended by the 2015-2020 Dietary Guidelines for American (Department 
Health and Human Services, 2015) and the 1.1 cup-equivalents per day of fruits and 1.6 cup-
equivalents per day of vegetables consumed by Americans (Hoy & Goldman et al., 2017). 
However, a 2-year randomized controlled trial studying the effects of the Mediterranean diet 
pattern on adults with metabolic syndrome reported fruit, vegetable, legume, and nut 
consumption of 487 g/day at the end of the trial compared to a baseline intake of 198 g/day 
(increase of 264 g/day) (Esposito et al., 2004), illustrating the ability of the Mediterranean diet 
pattern to promote plant food consumption, thereby increasing dietary intake of the 
phytochemicals that may prevent metabolic disease. 
 
1.5 Conclusions and Future Directions 
 The complexity of the associations between diet, the gastrointestinal microbiome, and 
inflammation is vast, but there are many quality studies on the topic. Animal studies have 
demonstrated differential effects of saturated and unsaturated fats on intestinal permeability and 
endotoxemia, but large-scale human trials are lacking. One potential obstacle for clinical 
research is the inability to easily access intestinal tissue for testing, but peripheral markers of 
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intestinal permeability may be able to partially overcome this. Many murine and human studies 
only differentiate between high- and low-fat diets or high-saturated and high-unsaturated fat 
diets, but additional studies on specific dietary fats and their effects on the microbiome, bile 
acids, and inflammation would be greatly beneficial as some researchers have found differential 
physiological effects of saturated fat from different food sources (i.e., milk fat vs. palm oil) 
(Brassard et al., 2017). Many murine studies also use supra-physiologic doses of dietary fat with 
low amounts of carbohydrates and fiber making them of questionable translational relevance 
(Cani et al., 2007; de Wit et al., 2012). Additionally, due to the TLR4-stimulating effects of some 
fatty acids, it is unclear in some studies of postprandial endotoxemia whether LPS or dietary fats 
are the source of inflammation. It should also be mentioned that saturated fats vary in their pro-
inflammatory ability. Preclinical research has demonstrated that medium chain triglyceride 
supplementation may ameliorate the obesogenic, diabetogenic, and pro-inflammatory effects of a 
high-fat diet (Geng et al., 2016). Similarly, a recent review demonstrates evidence that medium 
chain triglyceride intake may be related to the maintenance of metabolic health during obesity 
through mechanisms that involve the gastrointestinal microbiota (Rial et al., 2016). 
Research of fiber and health is also plagued by a lack of specificity with many studies 
measuring total grams of dietary fiber with no further differentiation (i.e., soluble vs. insoluble or 
fermentable vs. non-fermentable). Dietary fibers vary greatly in their impact on digestion, the GI 
microbiota, and health depending on chemical composition, degree of polymerization, and 
biological or synthetic origin (Holscher, 2017). Of specific interest is how fibers of differing 
solubility and fermentability impact bile acids, microbiota composition and function, and 
inflammation. Preclinical studies on fiber have found that high-fiber diets do improve barrier 
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function and decrease endotoxemia during a high-fat diet, but the ability to extrapolate these 
results to clinically significant reductions in metabolic disease risk has yet to be demonstrated. 
What clinical interventional studies exist for metabolic endotoxemia are scant (Table 1.3) 
and most use the LAL assay, which is an unreliable measure of plasma LPS concentration 
(Gnauck et al., 2015). Use of ELISA for LPS quantification should be regarded with similar 
skepticism (Munford, 2016). As the reliability and accuracy of measuring direct serum LPS 
concentrations is limited, researchers are encouraged to measure and report proxy measures like 
LPS-binding protein, inflammatory markers, and/or use cell-based methods (mononuclear cell 
stimulation with LPS) for a more accurate investigation of metabolic endotoxemia. 
Research on the microbiome is rapidly expanding due to technological and computational 
advances that make DNA sequencing cheaper and data analysis easier. However, current 
research is focused more on individual taxa and their contributions to the microbiome rather than 
the metabolic potential of the microbial community. As the major source of endotoxins in the 
body, the importance of characterizing diet-induced changes in the GI microbiota cannot be 
understated. Additional studies utilizing shotgun sequencing and multi-omic approaches will 
help answer the questions of which bacteria are present and what functional capacities they 
possess and their metabolic outputs. The bacterial metabolic processes of fermentation and bile 
acid modifications are of specific interest in investigating endotoxemia and inflammation. 
The area of inflammation and metabolic disease is better understood. Much has been 
done to characterize the inflammatory profiles of those with obesity and metabolic diseases. In 
addition, there is accumulating evidence on the beneficial effects of the Mediterranean diet 
pattern on metabolic syndrome (Kastorini et al., 2011; Meydani, 2005), diabetes (Salas-Salvado 
et al.,2011; Koloverou & Panagiotakos, 2017; Schroder et al., 2004), cardiovascular disease (Sofi 
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et al., 2010; Singh et al., 2002; Pastori et al., 2015; Estruch et al., 2013), and non-alcoholic fatty 
liver disease (Ryan et al., 2013; Kontogianni et al., 2014). Now is the time to further investigate 
mechanisms that inform dietary recommendations for the treatment and prevention of 
inflammatory metabolic disorders.  
While the crisis of obesity and its related comorbidities continues to deepen, there is a 
wealth of quality research occurring. Evidence of the efficacy of the Mediterranean diet in 
treating and preventing metabolic disease is abundant. Moving away from a Western diet pattern 
rich in red and processed meats, refined grains, and solid cooking fats toward a Mediterranean 
pattern rich in MUFAs and PUFAs from foods like nuts, avocados, salmon, and olive oil could 
help Americans meet dietary recommendations and improve metabolic health. Research of the 
mechanisms by which a Mediterranean diet pattern improves health, including modulation of the 
GI microbiota, endotoxemia, and inflammation is minimal and there is a need for large-scale 
comprehensive clinical trials.  
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Table 1.1. Comparison of Mediterranean and Western Diet Patterns 
1.(Sofi, 2010), 2.(Bonaccio et al., 2012), 3.(Leon-Munoz et al., 2012), 4.(Castro-Quezada et al., 
2014)
Comparison of Mediterranean and Western Diet Patterns 
Foods 
Level of Consumption 
Mediterranean (1) Western (2-4) 
Fresh Fruits and Vegetables High Low 
Whole Grains High Low 
Refined Grains Low High 
Legumes  High Low 
Nuts High No Specification 
Seafood Moderate No Specification 
Red and Processed Meats Low High 
Sugar-Sweetened Beverages Low High 
Red Wine Moderate No Specification 
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Table 1.2. Summary of Clinical Studies of the Mediterranean Diet Pattern  





Summary of Clinical Studies of the Mediterranean Diet Pattern 
Outcome Study Type Sample Size Treatment Reference 
A Mediterranean diet pattern 
may be effective in reducing 
the prevalence of metabolic 
syndrome 
Interventional 180 adults with metabolic syndrome 
Control – received advice to eat 
generalized healthful diet 
Treatment – received 
personalized advice to consume 
a Mediterranean diet pattern 
Esposito et al., 2004  
Consumption of a plant-based 
diet, consistent with high-
level adherence to the 
Mediterranean diet pattern, is 






vegetarian, or vegan diet 
NA De Filippis et al., 2015  
Adherence to a Mediterranean 
diet pattern was negatively 
associated with plasma 
endotoxin concentrations 
(evaluated by ELISA) and 
major adverse cardiovascular 
events, however no 
inflammatory markers were 
included 
Prospective 912 patients with atrial fibrillation NA Pastori et al., 2017 
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Table 1.3. Summary of Clinical Interventional Trials of Metabolic Endotoxemia 
TNF:  Tumor necrosis factor; IL: Interleukin; CRP: C-reactive protein; NFkB: nuclear factor kappa-light-chain-enhancer of activated B cells 
*Measured using the limulus amebocyte lysate (LAL) assay.  
Summary of Clinical Interventional Trials of Metabolic Endotoxemia 
Outcome Sample Size Treatment(s) and Control Endotoxin  
Inflammatory 
Markers Included Reference 








Control – no meal  
Treatments – ~900 kcal serving of 
toast with butter with or without 3 
cigarettes 









Control –  oatmeal, milk, orange 
juice, raisins, peanut butter, and 
English muffin  
Treatment – egg muffin and sausage 
muffin sandwiches and two hash 
browns 
­* TNF«, CRP«, NFkB­ Ghanim et al.,  2009 
A high-fat meal 
increased plasma 
endotoxin 








Treatment – 50g fat  





al.,  2012 
A high-saturated fat 




to a high-unsaturated fat 
or low-fat meal 
20 healthy 
adults 
Control – porridge made with olive 
oil (20% fat) 
Treatment – porridge made with 
fish oil, grapeseed oil, or coconut oil 
(35% fat) 
­* IL-6«, IL-8«, TNF« Lyte, 2016 
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Table 1.4. Summary of Preclinical Studies of Saturated Fat and Endotoxemia  
IL: Interleukin; TNF: Tumor necrosis factor 
*Measured using the limulus amebocyte lysate (LAL) assay.  **Assessed using the PyroGeneTM assay™ rFC Assay, Lonza™, Switzerlan
Summary of Preclinical Studies of Saturated Fat and Endotoxemia 
Outcome Model Treatment(s) and Control Endotoxin  Inflammatory Markers Included Reference 
High-saturated fat diet 
increased proportion of gram-




Control – standard murine diet 
Treatment - 72% energy from fat 
(corn oil and lard), 28% energy 
from protein, and >1% energy 
from carbohydrate 
­* 




Cani et al., 
2007 









Treatments – 45% of energy from 
fish oil or lard  ­* TNF­ 
Caesar et al., 
2015 
Saturated fat increased 
postprandial endotoxemia and 
treatment of ileal epithelium 
increased permeability to 
lipopolysaccharide 
Pig 
Control – porridge made with 
50ml water 
Treatments – porridge made with 
50ml of fish oil, vegetable oil, or 
coconut oil 
­** None Mani et al., 2013 
Arabinoxylan supplementation 
resulted in less fat mass 
development, better insulin 
sensitivity, greater gut integrity, 
less endotoxemia, less 
inflammation, a bloom of 
Bifidobacterium, cecal and 
colon enlargement, and an 
increase in colonic expression 




Control – high-fat (60% of 
energy) 
Treatment- high-fat diet 
supplemented with 7.5% (w/w) 
arabinoxylan extract 
¯* 
















5.(USDA nutrient database, 2016), 6. (Laugerette et al., 2012)
Lipid Composition of Fats and Oil (5) 













% PUFAs 37 29 11 7 10 7 10 12 
% MUFAs 29 64 81 79 39 7 49 47 
% Saturated 33 7 7 14 52 86 41 41 
w6/w3 0.07 2.08  NA 12.83 45.5 88.58 ‡ 10.2 
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CHAPTER 2: Plasma lipopolysaccharide-binding protein is associated with obesity, 




Background: Obesity and its related co-morbid conditions constitute a great health burden in the 
United States and other industrialized countries. Dietary strategies like the Mediterranean diet 
pattern may be efficacious in the treatment and prevention of overweight, obesity, and metabolic 
disease. The beneficial health effects of the Mediterranean diet pattern may be due in part to an 
increased consumption of dietary fiber compared to a Western diet pattern. Dietary fiber is well-
known for its anti-inflammatory effects, which may be due in part to the association between 
fiber and decreased endotoxemia. Methods: This cross-sectional study included 129 adult 
participants (mean age 33.8 ± 6.2 years) of varying weight status (mean BMI 30.4 ± 6.9) and 
without physician-diagnosed metabolic or gastrointestinal (GI) diseases. Participants provided 
blood and stool samples, completed medical and dietary history questionnaires, and underwent 
adiposity measurement. Results. Plasma C-reactive protein (CRP) and interleukin (IL)-6 
concentrations were related to multiple measures of adiposity. Plasma lipopolysaccharide-
binding protein (LBP) concentrations, a measure of endotoxemia, were related to dietary fiber 
intake, fecal concentrations of short-chain fatty acids, and whole-body percent fat. These results 




 Obesity is a worldwide epidemic on the rise with 921 million individuals suffering 
globally with overweight and obesity in 1980 and 2.1 billion individuals in 2013 (Sofi et al., 
2010). This increase in obesity is associated with a global shift toward the consumption of a 
Western-like dietary pattern, which is broadly characterized by high intake of refined 
carbohydrates, added sugars, and animal-sourced foods (Popkin et al., 2012). This Western 
pattern is often contrasted to the Mediterranean diet pattern, which is characterized by low 
consumption of refined carbohydrates, added sugars, and meat; moderate consumption of 
seafood and red wine; and high consumption of fruits, vegetables, legumes, nuts, and whole 
grains (Sofi et al., 2010). Compared to the Western dietary pattern, the Mediterranean diet 
pattern is associated with decreased inflammation (Chrysohoou et al., 2004), and lower rates of 
obesity (Mendez et al., 2006) and other metabolic diseases (Knoops et al., 2004).  
 Obesity is characterized by a state of chronic low-grade inflammation in the body (Cox et 
al., 2015) and this inflammation is increasingly understood as a mediator of the progression of 
metabolic disease. Plasma concentrations of key inflammatory markers like C-reactive protein 
(CRP) are elevated in obesity with one cross-sectional study reporting elevated CRP (> 10 mg/l) 
in 15% of those with obesity compared to only 3% of healthy weight individuals (Aronson et al., 
2004). In one longitudinal study, participants presenting with diabetes at the 5-year follow-up 
time-point were found to have 30% higher CRP concentrations at baseline compared to non-
converters (Festa et al., 2002). Similarly, a different cross-sectional study reported that those 
with clinically high CRP (>3 mg/l) and diabetes were at greatest risk of developing CVD (7.73 
[95% CI 3.99 –14.95; p<0.001]) compared to those with clinically high CRP but without 
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diabetes (1.99 [95% CI 1.10 –3.59; p<0.05]) and those with diabetes but clinically normal CRP 
(<1 mg/l) (3.21 [1.27–8.09; p<0.05]). 
 The cause of this inflammation is complex and involves interactions among diet, the 
gastrointestinal (GI) microbiota, GI barrier integrity, and the immune system. Metabolic 
endotoxemia, defined as a 2- to 3- fold increase in the amount of circulating lipopolysaccharide 
(LPS) (Cani et al., 2007), is increasingly implicated in obesogenic inflammation. The conditions 
that cause metabolic endotoxemia are not entirely elucidated but involve detrimental modulation 
of the GI microbiota due to poor diet quality (i.e., low dietary fiber), a weakening of GI barrier 
integrity, and inappropriate immune regulation (Bailey & Holscher, 2018).  
Several components of the Mediterranean diet pattern have been shown to reduce whole-
body inflammation, but dietary fiber was the focus of this report. Consumption of dietary fiber 
promotes beneficial changes in the GI microbiota, which lead to microbial production of anti-
inflammatory compounds, like butyrate, and decrease the passage of pathogen-associated 
molecular patterns like LPS into the blood steam (Bailey & Holscher, 2018). The anti-
inflammatory mechanisms of fiber consumption are under-investigated in adults with overweight 
and obesity. The aims of the present report were to assess the effects of dietary fiber intake on 
metabolic endotoxemia and inflammation as measured by pro-inflammatory monocyte markers 
and plasma concentrations of LPS-binding protein (LBP) and the pro-inflammatory cytokines 








Adult participants (n=129) undergoing testing as part of the baseline testing procedures 
(prior to interventions) of two clinical trials participated in the present study. Candidates were 
community-dwelling males and females aged 25-45 years with no physician-diagnosed 
metabolic, GI, or psychological diseases. Participants were excluded if they were pregnant or 
lactating, tobacco users, regular consumers of excessive amounts of alcohol, or taking 
medication known to affect GI function. This project was approved by the Institutional Review 
Board of the University of Illinois at Urbana-Champaign. 
 
2.2.2 Anthropometric measures and body composition 
Whole body adiposity was measured by dual-energy X-ray absorptiometry (DXA) 
(Hologic QDR 4500A bone densitometer, software version 13.4.2; Bedford, MA). Height (Seca 
model 240 stadiometer; Seca, Hamburg, Germany) and weight (Tanita WB-300 Plus digital 
scale; Tanita Corporation, Tokyo, Japan) were also collected. Body mass index (BMI) was 
calculated in kg/m2.  
 
2.2.3 Dietary analysis 
 Habitual dietary intake was assessed using the National Cancer Institute (NCI) online 
Diet History Questionnaire (DHQII, past year, with portion size).  Diet history questionnaires 




2.2.4 Microbiome analysis 
 Participants provided fecal samples (during recording of 7-day diet record) within 15 
minutes of defecation. Aliquots for microbiome analysis were homogenized, flash frozen with 
liquid nitrogen, and stored at -80 ºC. DNA extraction was conducted using the PowerLyzer 
PowerSoil Kit (MOBIO Laboratories, Inc., Carlsbad, CA). Integrity of extracted DNA was 
assessed with the E-Gel agarose gel electrophoresis system and quantified with the Qubit 3.0 
Fluorometer and double stranded DNA broad range assay kit (Life Technologies, Grand Island, 
NY). Microbial taxonomy, specifically the V4 region of the 16S rRNA gene 515F/806R primer 
set: 515F 5'-GTGCCAGCMGCCGCGGTAA, 806R 5'-GGACTACHVGGGTWTCTAAT, was 
assessed using high throughput sequencing (Illumina Miseq version 3, Illumina Inc., San Diego, 
CA) as previously described (Holscher et al., 2018). Operational taxonomic units were assigned 
using the Greengenes 13_8 database using QIIME version 2.0 (Callahan et al., 2016). Sequence 
analysis was conducted using the DADA2 denoise-single plugin using default settings and 
rarified following denoising, dereplication, and filtering procedures (Callahan et al., 2016). 
 
2.2.5 Microbial metabolite analyses 
Fecal sample aliquots for short-chain fatty acid (SCFA) analysis were weighed, acidified 
with 2N hydrochloric acid, and stored at -20 ºC. Before analysis, samples were thawed and 
centrifuged at 13,000 x g for 10 minutes. Gas-liquid chromatography (Hewlett-Packard 5890A 
Series II, 180cm x 4mm i.d. glass column with 10% SP-1200/1% HVFA H3PO4 on 80/100 mesh 
Chromosorb WAW, Supelco Inc., Bellefonte, PA) was used for quantification of SCFA 
(butyrate, propionate, and acetate) concentrations, which were normalized by dry matter weight 
as previously described (Holscher et al., 2015). 
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2.2.6 Flow cytometry analysis 
Participants reported to the laboratory after at least a 10-hour overnight fast. Blood was 
collected from the antecubital vein with ethylenediaminetetraacetic acid (EDTA)-anticoagulant-
coated tubes. Plasma was aliquoted after Ficoll-Paque (GE Life Sciences; Pittsburgh, PA) 
separation and prior to isolation of peripheral blood mononuclear cells (PBMCs). Samples were 
incubated with VioBlue conjugated CD14 (1:50; Miltenyi Biotec; Bergisch Gladbach, Germany), 
VioGreen conjugated CD16 (1:100; Miltenyi Biotec; Bergisch Gladbach, Germany), 
phycoerythrin (PE)-Vio770 conjugated TLR2 (1:100; Miltenyi Biotec; Bergisch Gladbach, 
Germany), allophycocyanin (APC) conjugated TLR4 (1:100; Miltenyi Biotec; Bergisch 
Gladbach, Germany), fluorescein (FITC) conjugated CD11a  (1:100; Miltenyi Biotec; Bergisch 
Gladbach, Germany) and PE conjugated CD71 (1:50; Miltenyi Biotec; Bergisch Gladbach, 
Germany). Gating for monocytes was conducted using CD14. Flow cytometric analysis was 
conducted using a Benton-Dickson Biosciences LSR II Flow Cytometer with Benton-Dickson 
FACSDiva software version 8.0.1 (Benton Dickinson Biosciences; San Jose, CA). FACSDiva 
software output was analyzed using FCS Express 6 Flow (De Novo Software; Glendale, CA). 
 
2.2.7 ELISA analysis  
EDTA plasma was utilized for enzyme-linked immunosorbent assay (ELISA) 
measurement of inflammatory markers CRP (Invitrogen; Carlsbad, CA, USA), LBP (Hycult 
Biotech; Uden, The Netherlands), alpha-1-acid glycoprotein (AGP) (R&D Systems; 
Minneapolis, MN, USA), and interleukin-6 (IL-6) (R&D Systems; Minneapolis, MN, USA). 
Heparin plasma was used for the ELISA measurement of the inflammatory marker tumor-
necrosis factor (TNF) (Alpco; Salem, NH, USA). 
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2.2.8 Statistical Analysis 
Markers of inflammation, dietary nutrient intake, anthropometric measures, fecal SCFA 
concentrations, and microbial relative abundances were first assessed for normality using the 
UNIVARIATE procedure. The TTEST and NPAR1WAY procedures were used to analyze sex 
differences for normally and non-normally-distributed variables, respectively. Then, bivariate 
correlations were conducted to inform later testing using the CORR procedure. Stepwise 
regression analyses were then conducted to determine predictors of LBP concentrations using the 
generalized linear mixed models (GLIMMIX) procedure in Statistical Analysis Software (SAS) 
(version 9.4; SAS Institute, Inc.) as previously described (Kaczmarek et al., 2017). Briefly, 
model fit was assessed using the ratio of the Chi-Square to its degrees of freedom. This ratio 
assesses residual variability that is not explained by the model (Schabenberger, 2005) and values 
<2 indicated appropriate model fit (Hooper et al., 2008). This procedure was performed step-
wise in order to assess confounding factors. In step 1, the predictors age, sex, and whole-body 
percent fat were assessed as each has been shown to be independently associated with systemic 
inflammation (Roubenoff et al., 1998; Thorand et al., 2006; Festa et al., 2001).  In step two, 
dietary fiber intake was added to the model.  In step 3, microbial-derived metabolites of fiber 
fermentation (acetate, propionate, and butyrate) were separately added. Lastly, in step 4, 
microbes known to produce the respective metabolites (i.e., acetate, propionate, and butyrate) 
were added into the model along with the other variables. Beta values were used to determine the 
direction and strength of relationships between variables. The standard coefficient estimate was 
used to estimate effect size.  A probability of p < 0.05 was accepted as significant and was not 




 Baseline characteristics of participants in this study, including age and BMI (Table 2.1.), 
measures of obesity (Table 2.2.), inflammatory markers (Table 2.3.), dietary intake as measured 
by DHQ (Table 2.4.), fecal SCFA concentrations (Table 2.5.), and relative abundance of 
relevant GI microbes (Table 2.6.) can be found in the corresponding tables. Analyses revealed a 
strong positive relationship between measures of adiposity and plasma concentrations of CRP 
and IL-6 (Table 2.7.), which has been well established in the literature (Park et al., 2004; 
Rexrode et al., 2003). A consistent, significant relationship between plasma LBP concentrations 
and measures of obesity, fecal SCFA concentrations, and intake of dietary fiber (Table 2.8.) was 
revealed. Plasma LBP concentrations differed significantly between females and males (Table 
2.9.). Because measures of obesity, fecal concentrations of SCFA, and dietary fiber intake also 
differed between the sexes (Table 2.9.), multiple analyses were conducted in the effort to 
determine if sex, adiposity, diet, or GI microbiota structure and function was the most predictive 
of plasma LBP concentrations. To accomplish this, generalized linear mixed modeling was 
utilized. In Tables 2.10-2.15., the results of these models are provided. The results revealed that 
total body fat, dietary fiber intake, and fecal SCFA are the most predictive of plasma LBP 
concentrations. Age, sex, and individual microbes were not related to plasma LBP concentrations 
when other explanatory variables were included in the model. 
  
2.4 Discussion 
The human body is increasingly recognized as a superorganism, with overall health being 
determined by complex relationships between microbe and host and the immune system being 
responsible for regulating those relationships (Dietert & Dietert, 2012). The innate immune 
 42 
system is the first line of defense against pathogens, acutely sensing molecular patterns 
associated with bacteria in the GI tract. These pathogen associated molecular patterns include 
lipoteichoic acid, a component of the gram-positive bacterial cell wall that is sensed by toll-like 
receptor (TLR)2, and LPS, a component of the gram-negative bacteria cell membrane that is 
sensed by TLR4 (Akira & Hemmi, 2003). Upon entry into circulation, LPS is captured by LPS-
binding protein, an acute phase protein secreted by the liver. LBP then complexes with soluble or 
membrane-bound CD14 and membrane-bound TLR4 to complete the sensory structure and 
initiate the downstream cascade of pro-inflammatory activity, which includes activation of 
multiple transcription factors including light-chain-enhancer of activated B cells (NF-κB) (Akira 
& Hemmi, 2003). NF-κB has long been established as a prominent facilitator of pro-
inflammatory activity whose activation induces the secretion of cytokines like TNF and IL-6, 
adhesion molecules, chemokines and chemoattractants, and various other immunoregulatory 
molecules (Hayden & Ghosh 2004). Monocytes and macrophages, the predominate immune cell 
populations possessing TLR4 for LPS sensing, facilitate the robust whole-body response to 
endotoxemia and are increasingly implicated in obesity-related inflammation (Caesar et al., 
2015). 
Much of the existing clinical literature investigating metabolic endotoxemia utilizes the 
limulus amebocyte lysate (LAL) assay for the quantification of LPS. The validity and 
reproducibility of the LAL assay for quantification of endotoxin in vivo is questionable (Gnauck 
et al., 2015). Other methods of direct plasma LPS quantification, including ELISA, should be 
met with similar skepticism (Munford, 2016). In this investigation, an indirect method of 
endotoxemia measurement (quantification of LPS-binding protein) was used. Some clinical trials 
have demonstrated a significant correlation between plasma endotoxin and LBP concentrations 
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(Rojo et al., 2007), while other clinical trials have found no significant relationship (Opal et al., 
1999). This discrepancy may be due to the inaccuracy of the LAL assay for endotoxin 
quantification or to the complexity of the relationship between endotoxin concentrations and the 
physiological response to endotoxemia. Murine studies utilizing multiple LBP knockout models 
have demonstrated that LBP is an essential component of the immune response to LPS along 
with CD14 (Le Roy et al., 1999). 
There is limited clinical research on the role of LBP in obesity and its related comorbid 
conditions. One cross-sectional study (n = 420) of adults of varying weight and metabolic health 
status investigated associations between LBP and various lifestyle and health factors, they 
reported that serum LBP concentrations were increased in individuals with obesity compared to 
those with a healthy weight (7.75 vs 5.90 µg/ml, p<0.001). Further, serum LBP concentrations 
were significantly higher in those with metabolic syndrome (8.02 vs 6.82 µg/ml, p<0.001) and 
were independently associated with abdominal obesity and the serum concentrations of pro-
inflammatory cytokines like IL-6 and soluble CD14 (Gonzalez-Quintela et al., 2013). Another 
cross-sectional study (n = 222) reported a significant increase in circulating LBP concentrations 
in those with morbid obesity and type-2 diabetes and a decrease in circulating LBP 
concentrations after weight loss (22.2 ± 5.8 vs 16.2 ± 9.3 μg/ml, p<0.0001) in association with 
changes in insulin sensitivity (Moreno-Navarrete et al., 2012). One prospective study evaluated 
the role of LBP in non-alcoholic fatty liver disease (NAFLD) in 40 adults with morbid obesity. 
Plasma LBP concentrations were increased in those with obesity and NAFLD, compared to those 
with obesity alone, and were highest in those with steatohepatitis (14.2 ±3.9 μg/mL) compared to 
simple steatosis (11.5 ±3.2 μg/mL) (Ruiz et al., 2007). These studies provide important evidence 
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of the role of LBP and metabolic endotoxemia in obesity and metabolic disease, however 
additional trials and meta-analyses are needed. 
In the present report, plasma LBP concentrations were significantly higher in females, 
which may be due to sample size as there were nearly twice the number of females compared to 
males. However, mechanistic reasons for higher plasma LBP concentrations in women may 
include a greater degree of adiposity in the females in this study or lower concentrations of fecal 
SCFA concentrations. Therefore, generalized linear mixed modeling was utilized with step-wise 
addition of predictor variables including age, sex, whole body percent fat, dietary fiber intake, 
fecal SCFA concentrations, and the relative abundance of relevant microbial genera to delineate 
this relationship. The stepwise approach allowed for the identification of the best fitting models 
to predict plasma LBP concentrations. Although sex was significantly related to LBP 
concentrations in early steps of the modeling, the relationship was no longer statistically 
significant when fecal SCFA concentrations, dietary fiber intake, and percent body fat were 
added to the model. Therefore, it was determined that the effect was likely not a consequence of 
simple sex differences in this sample. Rather, concentrations of LBP were best predicted by 
dietary fiber intake and the microbial-derived by-products, including acetate, propionate, and 
butyrate.  
These results are largely supported by the existing preclinical literature, which documents 
the effects of SCFAs, especially butyrate, on GI barrier function (Wang et al., 2012). The results 
did not reveal statistically significant relationships between microbes known to produce SCFA 
and plasma LBP concentrations in this study. This may be due to the complexity of the structure 
and function of the GI microbiota, especially the complex web of microbes involved in the 
production, consumption, and alteration of SCFAs, i.e., microbial cross-feeding. However, 
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butyrate-producing bacteria, like Faecalibacterium and Roseburia, have been found to be 
depleted in those with GI inflammatory disorders (Sokol et al., 2008), demonstrating the 
importance of microbiome structure and function in maintaining GI health. Localized GI 
inflammation and decreased GI barrier function due to SCFA scarcity can lead to greater whole-
body inflammation due to increased paracellular translocation of LPS from the GI lumen into the 
blood stream (Hur et al.,2015). Although the present study did not directly measure GI barrier 
integrity, the authors hypothesized that the interaction between low dietary fiber intake and low 
fecal SCFA concentrations and increased plasma LBP concentrations in the participants in this 
study may be due to alterations in barrier function leading to an increase in endoxotemia. Future 
work is needed to test this hypothesis.  
Obesity can be characterized as a state of chronic, subclinical inflammation (Cox et al., 
2015). The results reported herein support the existing body of evidence (Park et al., 2004; 
Rexrode et al., 2003) detailing the association between plasma CRP and IL-6 concentrations and 
obesity. Although there are many mechanisms by which obesity contributes to inflammation, 
including chronic hyperglycemia (King, 2008) and secretion of pro-inflammatory cytokines by 
adipose tissue (Caesar et al., 2015), this increase in plasma concentrations of CRP and IL-6 may 
also be due to increased endotoxemia. CRP is an acute phase protein that is highly responsive to 
LPS during gram-negative bacterial infections (Ng et al., 2004) and IL-6 increases in direct 
response to CRP (Park et al., 2005). Given that this participant population is free of diagnosed 
metabolic diseases, this relationship between adiposity and inflammation indicates the 
progressive and damaging nature of obesity and the need for more investigation of endotoxemia 
in individuals with varying levels of obesity and metabolic dysfunction. 
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2.5 Conclusions  
 Obesity and its related metabolic disorders continue to increase in prevalence around the 
world and strategies for prevention and treatment are of vital importance. Metabolic 
endotoxemia and inflammation is one facet in the progression of metabolic dysfunction and it is 
under-investigated, particularly in adults without diagnosed metabolic disease. Dietary strategies 
for the prevention of metabolic endotoxemia may be effective in preventing some comorbid 
conditions of obesity. Consumption of dietary fiber, which promotes whole-body health through 
a number of mechanisms, is a nutrient of particular interest in the prevention of metabolic 
endotoxemia. This report contributes valuable knowledge to the body of literature, which 
currently lacks clinical research on LBP concentrations in adults without diagnosed metabolic 
disease. This report also contributes to a large body of research detailing the relationship 
between adiposity and plasma CRP and IL-6 concentrations. 
 Future investigations should expand upon this research by including more measures of 
endotoxemia and GI barrier function.  
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Table 2.1. Descriptive characteristics of sample 
n = 131, 45 males Unit Mean Std Dev Min Max 
Age  Years 33.8 6.2 25 46 
BMI  kg/m2 30.4 6.9 18.3 57.6 
Std Dev, standard deviation; min, minimum; max, maximum; BMI, body mass index 
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Table 2.2. Descriptive characteristics of sample, measures of obesity 
N=128, 43 males Unit Mean Std Dev Min Max 
Visceral Fat kg 0.6 0.3 0.1 1.9 
Abdominal Fat kg 2.5 1.0 0.5 5.1 
Subcutaneous Fat kg 1.9 0.8 0.3 3.9 
Whole Body Percent Fat % 38.1 8.6 16.9 56.5 
Std Dev, standard deviation; min, minimum; max, maximum 
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Table 2.3. Descriptive characteristics of sample, inflammatory markers 
 Unit Sample Mean Std Dev Min Max 
CD16 % CD16+ cells n=112, 41 males 9.3 6.0 0.1 33.4 
TLR2 %TLR+ cells n=112, 41 males 34.7 29.5 0.1 99.9 
TLR4 %TLR4+ cells n=112, 41 males 22.5 16.2 1.3 75.9 
CD11A %CD11a+ cells n=112, 41 males 90.7 19.6 0.9 100.0 
CD71 %CD71+ cells n=107, 38 males 61.3 26.9 0.9 96.7 
CRP μg/ml n=120, 40 males 1.4 1.5 0.0 8.5 
LBP μg/ml n=114, 40 males 3.1 3.2 0.2 22.2 
AGP mg/ml n=120, 41 males 0.8 0.4 0.0 2.3 
IL-6 pg/ml n=117, 39 males 1.4 1.9 0.0 12.4 
TNF pg/ml n=103, 37 males 0.9 0.6 0.0 3.8 
Std Dev, standard deviation; min, minimum; max, maximum; CD16, cluster of differentiation 
16; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; 
CD71, cluster of differentiation 71; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor 
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Table 2.4. Descriptive characteristics of sample, dietary intake from the National Cancer 
Institute Online Diet History Questionnaire (DHQII, past year, with portion size)   
n=128, 45 males Unit Mean Std Dev Min Max 
Total Energy kcals 1739.8 731.7 434.7 4438.0 
Total Fat grams 74.7 33.7 19.6 167.6 
Total Carbohydrate grams 193.6 89.7 52.2 583.0 
Total Protein grams 69.0 32.4 14.5 162.6 
Dietary Fiber grams 15.2 6.7 2.4 38.3 
Dietary Fiber grams/1000 kcals 9.7 3.5 4.2 29.7 
Std Dev, standard deviation; min, minimum; max, maximum; kcals, kilocalories 
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Table 2.5. Descriptive characteristics of sample, fecal short-chain fatty acid concentrations 
n=129, 44 males Unit Mean Std Dev Min Max 
Acetate μmol/g DM 263.0 152.0 50.5 1044.0 
Propionate  μmol/g DM 76.2 55.8 7.9 428.0 
Butyrate μmol/g DM 62.1 48.4 4.4 253.0 
Std Dev, standard deviation; min, minimum; max, maximum; DM, dry matter 
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Table 2.6. Descriptive characteristics of sample, relative abundance of relevant fecal microbes 
n=128, 45 males Unit Mean Std Dev Min Max 
Faecalibacterium % of sequences 12.9 7.4 0.0 35.1 
Roseburia % of sequences 6.9 6.1 0.0 35.8 
Lachnospira % of sequences 1.5 2.0 0.0 13.4 
Bifidobacterium % of sequences 1.2 2.2 0.0 12.3 
Lactobacillus % of sequences 0.5 2.7 0.0 27.9 
Lachnobacterium % of sequences 0.1 0.4 0.0 3.6 
Akkermansia % of sequences 0.7 1.6 0.0 9.9 
Std Dev, standard deviation; min, minimum; max, maximum 
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Table 2.7. Bivariate correlations, plasma CRP and IL-6 are significantly positively associated 
with measures of obesity 
 CRP (μg/ml) *IL-6 (pg/ml) 
CRP (μg/ml) 1  
*IL-6 (pg/ml) rho=0.51, p=<0.0001, n=112 1 
Visceral Fat (kg) r=0.28, p=0.002, n=117 rho=0.38, p=<0.0001, n=114 
Abdominal Fat (kg) r=0.35, p=<0.0001, n=117 rho=0.42, p=<0.0001, n=114 
Subcutaneous Fat (kg) r=0.35, p=0.0001, n=117 rho=0.41, p=<0.0001, n=114 
% Body Fat r=0.34, p=0.0002, n=117 rho=0.35, p=0.0001, n=114 
CRP, c-reactive protein; IL-6, interleukin-6; *non-normally distributed  
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Table 2.8. Bivariate correlations, plasma LBP is significantly associated with fiber intake, fecal 
short-chain fatty acids, measures of obesity, and monocyte TLR4 expression 
 % TLR2 % TLR4 *LBP (μg/ml) 
% TLR2 1   
% TLR4 r=0.45, p=<0.001, n=112 1 
 
*LBP (μg/ml) rho=-0.07, p=0.48, n= 101 
rho=-0.21, p=0.03, 
n=101 1 


















































TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; LBP, lipopolysaccharide binding protein; 
DM, dry matter; *non-normally distributed  
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Table 2.9. Comparison of multiple factors between females and males 




 n = 86 n = 45  
 (Mean ± SEM) p value 
Plasma LBP (μg/ml) 3.4 ± 0.4 2.5 ± 0.4 <0.001* 
Visceral Fat (kg) 3.5 ± 0.1 3.7 ± 0.2 0.35 
Abdominal Fat (kg) 2.7 ± 0.1 2.2 ± 0.2 0.006 
Subcutaneous Fat (kg) 2.1 ± 0.1 1.5 ± 0.1 <.0001 
% Body Fat 41.9 ± 0.6 30.6 ± 1.2 <.0001 
Fecal Akkermansia (%) 0.9 ± 0.2 0.3 ± 0.1 0.03* 
Fecal A. muciniphila (%) 0.9 ± 0.2 0.3 ± 0.1 0.03* 
Fecal Acetate (μmol/g DM) 229.0 ± 13.4 326.0 ± 26.9 0.002 
Fecal Propionate (μmol/g DM) 63.5 ± 4.6 100.0 ± 10.3 0.0001* 
Fecal Butyrate (μmol/g DM) 52.2 ± 4.9 80.8 ± 7.4 <.0001* 
Dietary Fiber Intake (g/1000 kcals) 9.5 ± 0.3 8.2 ± 0.5 0.035 
*indicates use of Mann Whitney-Wilcoxon test for non-normally distributed variables, 
otherwise, T-test. SEM, standard error of mean; LBP, lipopolysaccharide binding protein; DM, 
dry matter 
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Table 2.10. Model of age, sex, body fat percentage, dietary fiber intake, fecal butyrate 
concentrations, and fecal Faecalibacterium abundance as predictors of plasma LBP 
concentrations in adults.   
 LBP 
 β p-value Std Coefficient Estimate 
Step 1    
Age -0.008 0.411 -0.528 
Sex -0.224 0.184 -1.120 
Total Body Fat 0.0179 0.051 1.621 
    
Step 2    
Age -0.002 0.797 -0.156 
Sex -0.335 0.049 -1.601 
Total Body Fat 0.021 0.027 1.817 
Dietary Fiber -0.059 0.002 -1.841 
    
Step 3    
Age -0.002 0.864 -0.101 
Sex -0.193 0.278 -0.915 
Total Body Fat 0.024 0.011 2.045 
Dietary Fiber -0.062 0.001 -1.912 
Butyrate -0.003 0.011 -1.490 
    
Step 4    
Age -0.001 0.912 -0.065 
Sex -0.175 0.330 -0.830 
Total Body Fat 0.025 0.009 2.132 
Dietary Fiber -0.063 0.001 -1.932 
Butyrate -0.003 0.010 -1.505 
Faecalibacterium 0.006 0.498 0.403 
Generalized linear mixed modeling, gamma distribution, step-wise with the addition of factors at 
each step for a total of 6 predictors. LBP, lipopolysaccharide binding protein 
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Table 2.11. Model of age, sex, body fat percentage, dietary fiber intake, fecal butyrate 
concentrations, and fecal Roseburia abundance as predictors of plasma LBP concentrations in 
adults.   
 LBP 
 β p-value Std coefficient Estimate 
Step 1    
Age -0.008 0.411 -0.528 
Sex -0.224 0.184 -1.120 
Total Body Fat 0.018 0.051 1.621 
    
Step 2    
Age -0.002 0.797 -0.156 
Sex -0.335 0.049 -1.601 
Total Body Fat 0.021 0.026 1.817 
Dietary Fiber -0.060 0.002 -1.841 
    
Step 3    
Age -0.002 0.864 -0.101 
Sex -0.193 0.278 -0.915 
Total Body Fat 0.024 0.011 2.045 
Dietary Fiber -0.062 0.001 -1.912 
Butyrate -0.0030 0.011 -1.490 
    
Step 4    
Age -0.001 0.935 -0.048 
Sex -0.212 0.238 -1.008 
Total Body Fat 0.023 0.014 1.987 
Dietary Fiber -0.061 0.001 -1.895 
Butyrate -0.003 0.008 -1.660 
Roseburia 0.011 0.396 0.550 
Generalized linear mixed modeling, gamma distribution, step-wise with the addition of factors at 
each step for a total of 6 predictors. LBP, lipopolysaccharide binding protein 
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Table 2.12. Model of age, sex, body fat percentage, dietary fiber intake, fecal butyrate 
concentrations, and fecal Lachnospira abundance as predictors of plasma LBP concentrations in 
adults.  
 LBP 
 β p-value Std coefficient Estimate 
Step 1    
Age -0.008 0.411 -0.528 
Sex -0.224 0.184 -1.120 
Total Body Fat 0.018 0.051 1.621 
    
Step 2    
Age -0.002 0.797 -0.156 
Sex -0.335 0.049 -1.601 
Total Body Fat 0.021 0.027 1.817 
Dietary Fiber -0.060 0.002 -1.841 
    
Step 3    
Age -0.002 0.864 -0.101 
Sex -0.193 0.278 -0.915 
Total Body Fat 0.024 0.011 2.045 
Dietary Fiber -0.062 0.001 -1.912 
Butyrate -0.003 0.011 -1.490 
    
Step 4    
Age -0.001 0.910 -0.067 
Sex -0.219 0.237 -1.038 
Total Body Fat 0.023 0.018 1.949 
Dietary Fiber -0.062 0.001 -1.904 
Butyrate -0.003 0.022 -1.398 
Lachnospira -0.017 0.616 -0.326 
Generalized linear mixed modeling, gamma distribution, step-wise with the addition of factors at 
each step for a total of 6 predictors. LBP, lipopolysaccharide binding protein 
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Table 2.13. Model of age, sex, body fat percentage, dietary fiber intake, fecal acetate 
concentrations, and fecal Bifidobacterium abundance as predictors of plasma LBP concentrations 
in adults.  
 LBP 
 β p-value Std coefficient Estimate 
Step 1    
Age -0.008 0.411 -0.528 
Sex -0.224 0.184 -1.120 
Total Body Fat 0.018 0.051 1.621 
    
Step 2    
Age -0.002 0.797 -0.156 
Sex -0.335 0.049 -1.601 
Total Body Fat 0.021 0.027 1.817 
Dietary Fiber -0.060 0.002 -1.841 
    
Step 3    
Age -0.001 0.903 -0.072 
Sex -0.186 0.297 -0.883 
Total Body Fat 0.0233 0.014 1.972 
Dietary Fiber -0.061 0.001 -1.884 
Acetate -0.001 0.008 -1.544 
    
Step 4    
Age -0.004 0.708 -0.221 
Sex -0.202 0.246 -0.960 
Total Body Fat 0.023 0.014 1.945 
Dietary Fiber -0.059 0.001 -1.843 
Acetate -0.001 0.042 -1.220 
Bifidobacterium -0.036 0.146 -0.852 
Generalized linear mixed modeling, gamma distribution, step-wise with the addition of factors at 
each step for a total of 6 predictors. LBP, lipopolysaccharide binding protein 
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Table 2.14. Model of age, sex, body fat percentage, dietary fiber intake, fecal acetate 
concentrations, and fecal Lactobacillus abundance as predictors of plasma LBP concentrations in 
adults.   
 LBP 
 β p-value Std coefficient Estimate 
Step 1    
Age -0.008 0.411 -0.528 
Sex -0.224 0.184 -1.120 
Total Body Fat 0.018 0.051 1.621 
    
Step 2    
Age -0.002 0.797 -0.156 
Sex -0.335 0.049 -1.601 
Total Body Fat 0.021 0.027 1.817 
Dietary Fiber -0.060 0.002 -1.841 
    
Step 3    
Age -0.001 0.903 -0.072 
Sex -0.186 0.297 -0.883 
Total Body Fat 0.0233 0.014 1.972 
Dietary Fiber -0.061 0.001 -1.884 
Acetate -0.001 0.008 -1.544 
    
Step 4    
Age -0.002 0.845 -0.117 
Sex -0.182 0.305 -0.867 
Total Body Fat 0.024 0.023 2.011 
Dietary Fiber -0.061 0.001 -1.869 
Acetate -0.001 0.022 -1.442 
Lactobacillus -0.023 0.673 -0.253 
Generalized linear mixed modeling, gamma distribution, step-wise with the addition of factors at 
each step for a total of 6 predictors. LBP, lipopolysaccharide binding protein 
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Table 2.15. Model of age, sex, body fat percentage, dietary fiber intake, fecal propionate 
concentrations, and fecal Akkermansia abundance as predictors of plasma LBP concentrations in 
adults.  
 LBP 
 β p-value Std coefficient Estimate 
Step 1    
Age -0.008 0.411 -0.528 
Sex -0.224 0.184 -1.120 
Total Body Fat 0.018 0.051 1.621 
    
Step 2    
Age -0.002 0.797 -0.156 
Sex -0.335 0.049 -1.601 
Total Body Fat 0.021 0.027 1.817 
Dietary Fiber -0.060 0.002 -1.841 
    
Step 3    
Age -0.002 0.834 -0.124 
Sex -0.194 0.282 -0.922 
Total Body Fat 0.023 0.014 1.979 
Dietary Fiber -0.062 0.001 -1.898 
Propionate -0.002 0.019 -1.378 
    
Step 4    
Age -0.003 0.744 -0.190 
Sex -0.150 0.405 -0.710 
Total Body Fat 0.024 0.010 2.039 
Dietary Fiber -0.060 0.001 -1.861 
Propionate -0.002 0.026 -1.305 
Akkermansia 0.042 0.134 0.728 
Generalized linear mixed modeling, gamma distribution, step-wise with the addition of factors at 
each step for a total of 6 predictors. LBP, lipopolysaccharide binding protein 
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CHAPTER 3: Investigation of the effects of avocado consumption on plasma and monocyte 
markers of inflammation 
 
Abstract 
Background: Dietary strategies for the treatment and prevention of obesity and its related co-
morbid conditions are important in addressing our current public health crisis. The 
Mediterranean diet pattern may be one strategy for promoting metabolic health due in part to the 
emphasis placed on foods rich in dietary fiber. Dietary fiber intake is associated with decreased 
rates of obesity and metabolic disease, which may be due in part to the ability of fiber to 
decrease metabolic endotoxemia, an inflammatory disorder associated with obesity. Avocados, 
rich in dietary fiber, unsaturated fats, and phytonutrients, exemplify several characteristics of the 
Mediterranean diet pattern. The primary objectives of this trial were to establish the effects of 
daily avocado consumption on adiposity, the gastrointestinal (GI) microbiota, and cognition. 
Herein, the secondary aims of this trial included investigation of avocado consumption on 
markers of inflammation in a subset of the study participants. Methods: Adult participants (n = 
96) aged 25-45 years with no physician diagnosed metabolic or GI diseases were provided with 
avocado daily for 12-weeks and provided blood and stool samples and underwent body 
composition measurement. Results. Within the entire cohort studied, avocado intake did not 
impact markers of inflammation compared to the control group. However, in participants who 
responded to the avocado intervention with an increase in fecal abundance of the butyrate-
producing genus Lachnobacterium or an increase in fecal short-chain fatty acid concentrations 
from baseline to 12-weeks did experience a significant decrease in plasma concentrations of 
lipopolysaccharide binding protein. 
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3.1 Introduction 
 Obesity rates continue to rise in the United States with 35.1% (Ogden et al., 2014) of 
adults affected. Dietary interventions may be efficacious in the prevention and treatment of 
overweight and obesity and one diet pattern of increasing interest is the Mediterranean diet 
pattern. Epidemiologically, consumption of the Mediterranean diet pattern, rich in dietary fiber, 
unsaturated fats, and phytonutrients has been associated with lower incidence of obesity and its 
related comorbid conditions (Schroder, 2007). Avocados exemplify the nutrient composition of 
the Mediterranean diet pattern, with one 100 g serving of flesh providing 6.8 g of dietary fiber, 
9.8 g of monounsaturated fatty acids, 1.8 g of polyunsaturated fatty acids, and 271 μg of the 
carotenoid phytonutrients lutein and zeaxanthin (USDA nutrient database). 
 One explanation for the decrease in disease risk associated with Mediterranean-type diets 
is the propensity of fiber to decrease inflammation. Multiple clinical trials have reported inverse 
relationships between dietary fiber intake and plasma concentrations of pro-inflammatory 
cytokines like C-reactive protein (CRP) (Ma et al., 2006). Similarly, analysis of 1999-2000 
NHANES data revealed an inverse relationship between dietary fiber intake and serum CRP 
concentrations (King et al., 2003). The anti-inflammatory effects of consumption of dietary fiber 
are likely due to a complex series of interactions with the gastrointestinal (GI) microbiota, GI 
physiology, and the immune system. Metabolic endotoxemia, defined as a 2- to 3- fold increase 
in the circulating concentrations of the pathogen associated molecular pattern lipopolysaccharide 
(LPS) is increasingly associated with the progression of obesity of metabolic disease (Cani 
2007). Dietary fiber, via modulation of the composition of the GI microbiota and production of 
bacterial fermentation end-products like the short-chain fatty acid (SCFA) butyrate, may prevent 
metabolic endotoxemia by decreasing translocation of LPS from the lumen of the gut into 
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circulation or by decreasing the pool of LPS available for translocation (Bailey & Holscher, 
2018). 
 The primary objectives of this trial were to test the hypothesis that that regular 
consumption of avocado reduces abdominal obesity and improves glycemic control, GI 
microbiota composition, and cognitive function among adults with overweight and obesity. In 
the present report, a secondary objective of this trial was investigated – the evaluation of the anti-
inflammatory effects of daily avocado consumption compared to a control treatment intended to 
mimic a Western dietary pattern (low in fiber, high in saturated fat). Analysis of this secondary 
outcomes presented herein was informed by treatment responder/non-responder results from the 
primary outcomes of this trial. The authors hypothesized that regular avocado consumption 
would lead to beneficial changes in the composition and function of the GI microbial 
community, decrease plasma endotoxin concentrations, and lower systemic inflammation. 
 
3.2 Research Design and Methods 
3.2.1 Study design 
The Persea americana for total health (PATH) study was an investigator-blinded, parallel 
arm, randomized controlled trial intended to investigate the effects of regular avocado 
consumption on abdominal obesity and glycemic control, composition of the GI microbiota, and 
cognitive function among adults with overweight and obesity. Participants received 1 prepared 
meal each day for 12 weeks which included 175 g (males) or 140 g (female) of fresh Hass 
avocado flesh in the intervention group or a meal matched for calories and fat in the control 




Participants were community-dwelling males and females aged 25-45 years with a BMI ≥ 
25.0 and no physician diagnosed metabolic, GI, or psychological diseases. Participants were 
excluded if they were pregnant or lactating, tobacco users, regular consumers of excessive 
amounts of alcohol, or taking medication known to affect GI function. This project was approved 
by the Institutional Review Board of the University of Illinois at Urbana-Champaign.  
 
3.2.3 Anthropometric measures and body composition 
Whole body composition was measured by dual-energy X-ray absorptiometry (DXA) 
(Hologic QDR 4500A bone densitometer, software version 13.4.2; Bedford, MA). Height (Seca 
model 240 stadiometer; Seca, Hamburg, Germany) and weight (Tanita WB-300 Plus digital 
scale; Tanita Corporation, Tokyo, Japan) were also collected. Body mass index (BMI) was 
calculated in kg/m2.  
 
3.2.4 Flow cytometry analysis 
Participants reported to the laboratory after at least a 10-hour overnight fast. Blood was 
collected from the antecubital vein with Ethylenediaminetetraacetic acid (EDTA)-anticoagulant-
coated tubes. Plasma was aliquoted after Ficoll-Paque (GE Life Sciences; Pittsburgh, PA) 
separation and prior to isolation of peripheral blood mononuclear cells (PBMCs). Samples were 
incubated with VioBlue conjugated CD14 (1:50; Miltenyi Biotec; Bergisch Gladbach, Germany), 
VioGreen conjugated CD16 (1:100; Miltenyi Biotec; Bergisch Gladbach, Germany), 
phycoerythrin (PE)-Vio770 conjugated TLR2 (1:100; Miltenyi Biotec; Bergisch Gladbach, 
Germany), allophycocyanin (APC) conjugated TLR4 (1:100; Miltenyi Biotec; Bergisch 
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Gladbach, Germany), fluorescein (FITC) conjugated CD11a  (1:100; Miltenyi Biotec; Bergisch 
Gladbach, Germany) and PE conjugated CD71 (1:50; Miltenyi Biotec; Bergisch Gladbach, 
Germany). Gating for monocytes was conducted using CD14. Flow cytometric analysis was 
performed using a BD Biosciences LSR II Flow Cytometer with BD FACSDiva 8.0.1 (Benton 
Dickinson Biosciences; San Jose, CA). FACSDiva software output was analyzed using FCS 
Express 6 Flow (De Novo Software; Glendale, CA). 
 
3.2.5 ELISA analysis 
EDTA plasma was utilized for enzyme-linked immunosorbent assay (ELISA) 
measurement of inflammatory markers CRP (Invitrogen; Carlsbad, CA, USA), 
lipopolysaccharide (LPS)-binding protein (LBP) (Hycult Biotech; Uden, The Netherlands), 
alpha-1-acid glycoprotein (AGP) (R&D Systems; Minneapolis, MN, USA), and interleukin-6 
(IL-6) (R&D Systems; Minneapolis, MN, USA). Heparin plasma was used for the ELISA 
measurement of the inflammatory marker tumor-necrosis factor (TNF) (Alpco; Salem, NH, 
USA). 
 
3.2.6 Microbiome analysis  
 Participants were instructed to return fecal samples to the laboratory within 15 minutes of 
defecation. Fecal aliquots were collected and flash frozen using liquid nitrogen before storage at 
-80C until further analysis was conducted. Following DNA isolation (PowerLyzer PowerSoil, 
Qiagen; Hilden, Germany) the bacterial amplicon (V4 region of 16S rRNA) were generated 
using a Fluidigm Access Array followed by high-throughput sequencing on an Illumina MiSeq. 
Sequences were quality filtered, then operational taxonomic units were picked against the 
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Greengenes 13-8 reference database using QIIME version 2.0 (Callahan et al., 2016). Sequence 
analysis was conducted using the DADA2 denoise-single plugin using default settings and 
rarified following denoising, dereplication, and filtering procedures (Callahan et al., 2016). 
 
3.2.7 Statistical Analysis 
 Markers of inflammation were analyzed with the GLM procedure in Statistical Analysis 
Software (SAS) (version 9.4; SAS Institute, Inc.) in per-protocol (PP; > 80% meal consumption) 
and intent-to-treat (ITT) samples with time and treatment as fixed effects. The UNIVARIATE 
procedure was used to test for data normality and log transformations were utilized as needed. 
The TTEST and NPAR1WAY procedures were used, depending on normality of the variable 
distributions, to determine differences between treatment groups. A probability value of <0.05 
was used as a marker of statistical significance. The ITT dataset was stratified using multiple 
separate variables known to be main treatment effects including sex, microbial abundances, fecal 
SCFA concentrations, and measures of adiposity. T-tests and equivalent non-parametric tests 
(Wilcoxin/Mann-Whitney-U) were used with these stratified datasets for the comparison of 
inflammation markers between treatment groups. 
 
3.3 Results 
 Of the 163 participants randomized, 96 provided blood samples for ELISA and flow 
cytometry analysis (49 in the control group, 47 in the intervention group). One participant was 
removed due to failure to complete baseline testing. Baseline characteristics of the ITT group can 
be found in Table 3.1. Treatment groups were not significantly statistically different at baseline 
in age or BMI, however some trending and significant differences in inflammation exist. 
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Baseline characteristics of the PP group can be found in Table 3.2. There were no significant 
differences between PP treatment groups. 
 Analysis revealed no trending or significant differences in inflammatory markers due to 
treatment effect in either the ITT (Table 3.3.) or PP (Table 3.4.) groups. Treatment effect was 
investigated separately in females and males due to differences in adiposity and fecal total SCFA 
at baseline. No trending or significant differences in inflammation due to treatment were detected 
in the female-only (Table 3.5.) or male-only (Table 3.6.) subsets of the ITT dataset. Neither did 
the results reveal any trending or significant differences in inflammatory markers in the female-
only (Table 3.7.) or male-only (Table 3.8.) subsets of the PP dataset due to treatment.   
Because this study is an exploratory investigation of secondary outcomes, responder 
analyses, based on results from the primary outcomes of the trial, were pursued. This approach 
included evaluation of change in inflammatory markers in those participants who had statistically 
significant alterations in the relative abundances of GI microbes, fecal concentration of SCFAs, 
and measures of visceral adiposity, which were outcomes in the primary report. Few significant 
or trending relationships existed between ITT treatment groups in those participants who had an 
increase the fecal relative abundance of the genera Faecalibaterium (Table 3.9.), Lachnospira 
(Table 3.10.), Lachnobacterium (Table 3.11.); an increase in the fecal concentrations of the 
SCFA acetate (Table 3.12.) or the sum of SCFAs (acetate, propionate, and butyrate) (Table 
3.13.); or a decrease in visceral fat mass (Table 3.14.) or the ratio of visceral to subcutaneous fat 
mass (Table 3.15.). These results did reveal that one inflammatory factor, plasma LBP 
concentrations, was decreased in participants who responded to the avocado treatment with 
increased fecal relative abundance of Lachnobacterium (Table 3.11.) and fecal concentrations of 
acetate (Table 3.12.) and SCFA sum (Table 3.13.). 
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3.4 Discussion 
  The aim of the current report was to assess the impact of daily avocado consumption on 
whole-body inflammation. There were few main effects of treatment on inflammation, as 
measured by plasma inflammatory cytokines or monocyte cell morphology. However, in 
participants who responded to the intervention with an increased relative abundance of fecal 
Lachnobacterium and increased fecal concentration of acetate and all SCFAs summed, there was 
a significant or trending decrease in plasma concentrations of LBP. These results are supported 
by the preclinical literature, which documents the ability of the SCFA butyrate to increase GI 
barrier integrity and decrease translocation of LPS from the GI lumen into the blood stream 
(Wang et al, 2012) thus decreasing plasma concentrations of LBP.  
 Following translocation from the GI lumen into circulation, LPS is captured by LPS-
binding protein, an acute phase protein secreted by the liver, that complexes with TLR4 and 
CD14 to form the sensing structure for LPS. Activation of this sensory compound induces 
signaling cascades in monocytes and macrophages, the immune cell population most responsive 
to endotoxemia, including the activation of transcription factors like light-chain-enhancer of 
activated B cells (NF-κB) (Akira & Hemmi, 2003). NF-κB is a prominent inducer of pro-
inflammatory activity including the secretion of cytokines like TNF and IL-6, adhesion 
molecules, and chemokines (Hayden & Ghosh 2004). Direct quantification of serum LPS is not 
currently possible due to a lack of a reliable assay, as both the limulus amoebocyte lysate assay 
(Gnauck et al., 2015) and ELISA method (Munford, 2016) fail to produce consistent, 
reproducible results. Thus, the quantification of LBP by ELISA was chosen as an indirect 
measure of endotoxemia. 
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 Although limited, there exists some clinical evidence for the role of LBP in obesity and 
metabolic disease, including one cross-sectional studies which reported increased serum LBP 
concentrations in adults with obesity and metabolic syndrome compared to adults with a healthy 
weight and no metabolic syndrome. The authors also report an association between serum LBP 
concentrations and serum concentrations of other pro-inflammatory cytokines like IL-6 and 
soluble CD14 (Gonzalez-Quintela et al., 2013). Increased circulating LBP concentrations have 
also been reported in adults with type-2 diabetes (Moreno-Navarrete et al., 2012) and non-
alcoholic fatty liver disease and steatohepatitis (Ruiz et al., 2007). Unfortunately, a gap exists in 
the literature of the effect of dietary fiber intake on serum LBP concentrations. 
 As with other members of the family Lachnospiraceae, Lachnobacterium is a known 
producer of butyrate (Whitford et al., 2001). Butyrate-producing bacteria are well-characterized 
in the literature for their beneficial effects on gut and whole-body health. Intestinal exposure to 
butyrate has been associated with a decreased risk of a wide range of disease from colon cancer 
(Archer et al., 1998) to type-2 diabetes (Gao et al., 2009). In vitro studies have shown the potent 
effects of butyrate on GI physiology, including the inhibition of inflammation and the 
reinforcement of gut barrier integrity (Hamer et la., 2008). Butyrate acts directly on the intestinal 
mucosa, increasing the expression of tight junction proteins and the rate of tight junction 
assembly. And when exposed to butyrate in vitro, rat intestinal cells increase the production of 
the protein claudin-1, a vital component of gut barrier structure (Wang et al., 2012). Human 
intestinal cells behave similarly in vitro upon butyrate exposure, increasing the activity of 
adenosine monophosphate-activated protein kinase, which tightens gap-junctions and barrier 
strength (Peng et al.,2009). This type of mechanistic research is difficult to conduct to conduct in 
clinical populations. However, the lactulose mannitol test is accepted as a method of measuring 
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gut permeability in humans (Zhang et al., 2000) and should be considered in future clinical 
studies of metabolic endotoxemia. 
 These largely null results may be due to three factors, 1) this cohort is younger and more 
metabolically healthy than tradition samples for inflammatory research; 2) the dose of avocado 
may not have been sufficient to cause the hypothesized effects; 3) as a secondary outcome of this 
trial, statistical power may have been inadequate to detect statically signficiant difference 
between group due to small sample size and/or large variation in responses among participants in 
the study. Future trials focusing on the investigation of metabolic endotoxemia as a primary 
outcome, may be more successful with a greater dose of dietary fiber or larger sample size.  
 
3.5 Conclusion 
 Obesity and metabolic syndrome affect an increasing proportion of adults in the US and 
one strategy for the prevention and treatment of obesity and metabolic syndrome is 
recommending healthy dietary patterns including the Mediterranean diet pattern. There is an 
increasing amount of research to suggest a Mediterranean diet pattern, rich in dietary fiber and 
low in saturated fat, is associated with lower all-cause mortality. Avocados, due to their fiber, fat, 
and phytonutrient composition, exemplify the beneficial components of a Mediterranean diet 
pattern. The aim of the current report was to assess the effects of daily avocado consumption 
(175g in males, 140g in females) on healthy adults with overweight and obesity. There were few 
statistically significant or trending differences in inflammation due to treatment effect, however 
there responder analyses do provide evidence for an association between plasma LBP 
concentrations, fecal short-chain fatty acid concentrations, and butyrate-producing bacteria. 
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 Future studies which utilize a more drastic dietary intervention, sample a more 
metabolically-ill population, or include a larger sample size may be better-equipped to address 




















*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests; SEM, standard error of mean; BMI, body mass index; CD16, cluster of differentiation-16; 
TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71; CRP, 
c-reactive protein; LBP, Lipopolysaccharide binding protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor 
necrosis factor 
  




 n = 49, 17 males n = 47, 17 males   
  (Mean ± SEM) p value 
Age years 34.0 ± 0.9 34.1 ± 0.8 0.9 
BMI kg/m2 32.0 ± 1.0 32.2 ± 1.0 0.9 
CRP μg/ml 1.7 ± 0.2 1.3 ± 0.2 0.2 
LBP μg/ml 2.4 ± 0.0 3.5 ± 0.2 0.8* 
AGP mg/ml 0.8 ± 0.1 0.7 ± 0.0 0.3 
IL-6 pg/ml 1.4 ± 0.1 1.8 ± 0.4 0.8* 
TNF pg/ml 0.9 ± 0.9 0.9 ± 0.1 0.8 
CD16 % CD16+ Cells 8.8 ± 0.6 9.2 ± 0.6 0.6 
TLR2 % TLR2+ Cells 39.1 ± 3.3 44.0 ± 3.3 0.3 
TLR4 % TLR4+ Cells 22.2 ± 1.6 26.3 ± 1.8 0.1 
CD11a % CD11a+ Cells 94.8 ± 1.5 96.7 ± 1.0 0.1* 
CD71 % CD71+ Cells 64.5 ± 2.6 68.3 ± 2.8 0.3 
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Table 3.2. Descriptive characteristics of the per-protocol treatment groups at baseline 
  




 n = 28, 13 males  n = 32, 14 males   
  (Mean ± SEM) p value 
Age years 33.5 ± 1.2 34.2 ± 1.0 0.6 
BMI kg/m2 21.8 ± 1.1 32.6 ± 1.1 0.6 
CRP μg/ml 1.6 ± 0.3 1.2 ± 0.2 0.4* 
LBP μg/ml 2.2 ± 0.1 3.7 ± 0.8 0.6* 
AGP mg/ml 0.1 ± 0.1 0.7 ± 0.1 0.4 
IL-6 pg/ml 1.1 ± 0.2 2.1 ± 0.5 0.4* 
TNF pg/ml 0.9 ± 0.2 0.9 ± 0.1 0.9* 
CD16 % CD16+ Cells 9.3 ± 1.1 10.2 ± 1.2 0.6 
TLR2 % TLR2+ Cells 31.7 ± 5.0 42.3 ± 5.1 0.1 
TLR4 % TLR4+ Cells 23.4 ± 3.3 27.1 ± 3.0 0.4 
CD11a % CD11a+ Cells 90.2 ± 3.7 95.5 ± 2.0 0.2* 
CD71 % CD71+ Cells 60.6 ± 4.9 64.6 ± 5.6 0.2 
**Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests; SEM, standard error of mean; BMI, body mass index; CD16, cluster of differentiation-16; 
TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71; CRP, 
c-reactive protein; LBP, Lipopolysaccharide binding protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor 
necrosis factor 
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Table 3.3. Effect of avocado consumption on markers of inflammation in the intent-to-treat treatment groups 




 Baseline 12-Week Baseline 12-Week  
 n = 49, 17 males n = 47, 17 males  
 (Mean ± SEM) p value 
CRP* μg/ml 1.7 ± 0.2 1.6 ± 0.2 1.3 ± 0.2 1.3 ± 1.7 0.7 
LBP* μg/ml 2.4 ± 0.2 2.4 ± 0.2 3.5 ± 0.2 2.8 ± 2.3 0.6 
AGP mg/ml 0.8 ± 0.1 0.8 ± 0.0 0.7 ± 0.0 0.7 ± 0.3 0.8 
IL-6 * pg/ml 1.4 ± 0.1 1.5 ± 0.2 1.8 ± 0.4 1.3 ± 1.6 0.9 
TNF* pg/ml 0.9 ± 0.9 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.4 0.8 
CD16 % CD16+ Cells 8.6 ± 5.4 8.9 ± 0.8 9.8 ± 6.4 8.8 ± 5.1 0.5 
TLR2 % TLR2+ Cells 38.2 ± 29.9 39.7 ± 4.6 44.9 ± 31.7 42.3 ± 23.7 0.9 
TLR4 % TLR4+ Cells 23.8 ± 15.2 21.1 ± 2.0  26.2 ± 17.1 25.2 ± 17.2 0.7 
CD11a % CD11a+ Cells 93.1 ± 15.6 94.5 ± 1.8 96.1 ± 10.1 96.3 ± 9.2 NA** 
CD71 % CD71+ Cells 64.5 ± 23.6 65.1 ± 3.7 66.1 ± 27.9 70.6 ± 23.1 0.7 
Statistical comparisons between groups were done using ANOVA, time by treatment interaction.  *Indicates log transformation to 
correct for non-normal distribution prior to analysis using ANOVA; **Indicates that the data remained non-normal after 
transformation. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding protein; AGP, alpha-1-acid 
glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, toll-like receptor 2; TLR4, 
toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71. 
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Table 3.4. Effect of avocado consumption on markers of inflammation in the per-protocol treatment groups 




 Baseline 12-Week Baseline 12-Week  
n= 28, 13 males 32, 14 males  
 (Mean ± SEM) p value 
CRP* μg/ml 1.6 ± 0.3 1.5 ± 0.3 1.2 ± 0.2 1.2 ± 0.2 0.9 
LBP* μg/ml 2.2 ± 0.1 2.4 ± 0.2 3.7 ± 0.8 2.9 ± 0.5 0.6 
AGP mg/ml 0.8 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.9 
IL-6 * pg/ml 1.1 ± 0.2 1.4 ± 0.2 2.1 ± 0.54 1.5 ± 0.3 0.3 
TNF pg/ml 0.9 ± 0.2 0.8 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.9 
CD16 μg/ml 9.3 ± 1.1 9.7 ± 1.1 10.2 ± 1.2 9.5 ± 1.0 0.6 
TLR2 μg/ml 31.7 ± 4.9 32.4 ± 5.2 42.3 ± 5.1 43.2 ± 4.8 0.9 
TLR4 mg/ml 23.4 ± 3.3 20.1 ± 3.0 27.1 ± 3.0 26.5 ± 3.1 0.7 
CD11a pg/ml 90.1 ± 3.7 95.3 ± 1.9 95.5 ± 2.0 96.0 ± 1.8 NA 
CD71 pg/ml 60.6 ± 4.9 62.4 ± 4.6 64.6 ± 5.5 73.1 ± 4.0 0.5 
Statistical comparisons between groups were done using ANOVA, time by treatment interaction.  *Indicates log transformation to 
correct for non-normal distribution prior to analysis using ANOVA. SEM, standard error of mean; CRP, c-reactive protein; LBP, 
Lipopolysaccharide binding protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster 
of differentiation-16; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of 
differentiation 71 
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Table 3.5. Effects of avocado consumption on markers of inflammation in females in the intent-to-treat treatment groups   




  Baseline 12-week Baseline 12-week  
  n = 32 females n = 29 females  
  (Mean ± SEM) p value 
CRP* μg/ml 1.8 ± 0.2 2.1 ± 0.4 1.5 ± 0.3 1.7 ± 0.4 0.8 
LBP* μg/ml 2.7 ± 0.2 2.7 ± 0.2 3.8 ± 0.9 3.0 ± 0.4 0.9 
AGP mg/ml 0.8 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.9 
IL-6* pg/ml 1.5 ± 0.3 1.4 ± 0.2 1.8 ± 0.5 1.8 ± 0.4 0.9 
TNF pg/ml 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.9 
CD16 % CD16+ Cells 9.1 ± 1.2 9.0 ± 1.3 10.7 ± 1.3 9.0 ± 1.2 0.5 
TLR2 % TLR2+ Cells 39.2 ± 6.2 35.0 ± 6.5 48.3 ± 6.4 38.7 ± 5.3 0.6 
TLR4 % TLR4+ Cells 19.8 ± 2.9 20.2 ± 3.5 25.6 ± 3.1 21.0 ± 2.9 0.4 
CD11A % CD11a+ Cells 93.6 ± 2.3 96.8 ± 1.1 96.1 ± 1.9 94.0 ± 2.5 NA** 
CD71 % CD71+ Cells 65.0 ± 5.3 66.2 ± 5.2 66.8 ± 6.0 70.4 ± 5.8 0.8 
Statistical comparisons between groups were done using ANOVA, time by treatment interaction.  *Indicates log transformation to 
correct for non-normal distribution prior to analysis using ANOVA; **Indicates that the data remained non-normal after 
transformation. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding protein; AGP, alpha-1-acid 
glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, toll-like receptor 2; TLR4, 
toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.6. Effects of avocado consumption on markers of inflammation in males in the intent-to-treat treatment groups   




  Baseline 12-week Baseline 12-week  
  n = 17 males n = 17 males  
  (Mean ± SEM) p value 
CRP* μg/ml 1.4 ± 0.6 1.0 ± 0.3 1.0 ± 0.3 0.9 ± 0.5 0.6 
LBP* μg/ml 1.8 ± 0.1 2.0 ± 0.2 3.1 ± 0.9 2.6 ± 0.8 0.4 
AGP mg/ml 0.7 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.8 
IL-6* pg/ml 1.2 ± 0.3 1.1 ± 0.2 1.7 ± 0.7 0.9 ± 0.2 0.9 
TNF pg/ml 0.9 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.5 
CD16 % CD16+ Cells 7.8 ± 1.0 9.5 ± 1.5 8.1 ± 1.5 9.4 ± 1.4 0.9 
TLR2 % TLR2+ Cells 36.7 ± 7.2 32.5 ± 7.3 38.9 ± 7.9 43.9 ± 7.8 0.5 
TLR4 % TLR4+ Cells 30.0 ± 3.6 22.0 ± 4.1 27.3 ± 5.1 31.6 ± 5.2 0.2 
CD11A % CD11a+ Cells 91.9 ± 5.2 91.7 ± 3.9 96.2 ± 2.9 98.1 ± 1.1 NA** 
CD71 % CD71+ Cells 62.1 ± 5.3 52.6 ± 7.4 64.9 ± 6.4 72.3 ± 3.5 0.2 
Statistical comparisons between groups were done using ANOVA, time by treatment interaction.  *Indicates log transformation to 
correct for non-normal distribution prior to analysis using ANOVA; **Indicates that the data remained non-normal after 
transformation. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding protein; AGP, alpha-1-acid 
glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, toll-like receptor 2; TLR4, 
toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71
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Table 3.7. Effects of avocado consumption on markers of inflammation in females in the per-protocol treatment groups   




  Baseline 12-Week Baseline 12-Week  
  n = 15 females n = 18 females  
  (Mean ± SEM) p value 
CRP μg/ml 1.6 ± 0.3 2.0 ± 0.4 1.4 ± 0.3 1.5 ± 0.3 0.6 
LBP* μg/ml 2.4 ± 0.2 2.8 ± 0.3 4.1 ± 1.3 3.0 ± 0.5 0.6 
AGP mg/ml 0.9 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.9 
IL-6 * pg/ml 1.2 ± 0.2 1.6 ± 0.2 2.2 ± 0.7 1.8 ± 0.5 0.4 
TNF pg/ml 0.9 ± 0.3 0.8 ± 0.1 0.9 ± 0.1 0.7 ± 0.1 0.8 
CD16 μg/ml 10.7 ± 1.8 10.5 ± 1.5 11.4 ± 1.7 9.4 ± 1.4 0.6 
TLR2 μg/ml 27.5 ± 6.4 33.2 ± 7.4 42.3 ± 6.4 40.2 ± 6.1 0.5 
TLR4 mg/ml 18.2 ± 5.1 17.4 ± 3.9 26.3 ± 3.4 21.6 ± 3.3 0.6 
CD11a pg/ml 90.1 ± 4.1 96.9 ± 1.2 95.4 ± 2.6 94.6 ± 2.9 NA 
CD71 pg/ml 59.8 ± 7.9 68.8 ± 3.6 64.8 ± 8.2 73.0 ± 6.4 0.9 
Statistical comparisons between groups were done using ANOVA, time by treatment interaction.  *Indicates log transformation to 
correct for non-normal distribution prior to analysis using ANOVA; **Indicates that the data remained non-normal after 
transformation. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding protein; AGP, alpha-1-acid 
glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, toll-like receptor 2; TLR4, 
toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.8. Effects of avocado consumption on markers of inflammation in males in the per-protocol treatment groups   




    Baseline 12-Week Baseline 12-Week   
   n = 13 males n = 14 males   
    (Mean ± SEM) p value 
CRP μg/ml 1.7 ± 0.7 1.0 ± 0.3 0.8 ± 0.3 1.0 ± 0.5 0.4 
LBP* μg/ml 1.9 ± 0.1 2.0 ± 0.2 3.1 ± 1.0 2.8 ± 0.9 0.8 
AGP mg/ml 0.7 ± 0.1 0.8 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.9 
IL-6 * pg/ml 1.1 ± 0.2 1.1 ± 0.2 1.9 ± 0.9 0.9 ± 0.2 0.6 
TNF pg/ml 1.0 ± 0.1 0.8 ± 0.1 0.8 ± 0.2 0.71 ± 0.1 0.7 
CD16 μg/ml 7.9 ± 1.2 8.8 ± 1.5 8.6 ± 1.7 9.6 ± 1.5 0.9 
TLR2 μg/ml 35.8 ± 7.6 31.6 ± 7.6 42.2 ± 8.7 47.4 ± 8.1 0.6 
TLR4 mg/ml 28.6 ± 3.8 23.0 ± 4.6 28.3 ± 5.7 33.3 ± 5.5 0.3 
CD11a pg/ml 90.2 ± 6.4 93.6 ± 3.6 95.6 ± 3.3 98.1 ± 1.1 NA** 
CD71 pg/ml 61.5 ± 6.1 54.8 ± 8.7 64.3 ± 7.4 73.5 ± 3.5 0.2 
Statistical comparisons between groups were done using ANOVA, time by treatment interaction.  *Indicates log transformation to 
correct for non-normal distribution prior to analysis using ANOVA; **Indicates that the data remained non-normal after 
transformation. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding protein; AGP, alpha-1-acid 
glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, toll-like receptor 2; TLR4, 
toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71
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Table 3.9. Effects of avocado consumption on markers of inflammation in participants who had an increase in the fecal relative 
abundance of the genus Faecalibacterium 




 n = 18, 7 males n = 16, 6 males  
 (Mean ± SEM) p value 
Δ CD16 -0.31 ± 1.70 -1.96 ± 1.56 0.48 
Δ TLR2 -7.35 ± 3.89 5.08 ± 5.51 0.16* 
Δ TLR4 -7.57 ± 4.80 -1.82 ± 3.16 0.33 
Δ CD11a 0.97 ± 1.14 -1.91 ± 2.60 0.83* 
Δ CD71 -4.77 ± 3.45 2.23 ± 3.52 0.17 
Δ CRP -0.36 ± 0.58 -0.03 ± 0.36 0.64* 
Δ LBP 0.28 ± 0.13 -1.37 ± 1.15 0.18* 
Δ AGP -0.04 ± 0.10 -0.01 ± 0.07 0.84 
Δ IL6 -0.03 ± 0.28 -0.61 ± 0.31 0.17 
Δ TNF -0.06 ± 0.10 -0.15 ± 0.12 0.57 
*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, 
toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.10. Effects of avocado consumption on markers of inflammation in participants who had an increase in the fecal relative 
abundance of the genus Lachnospira 




 n = 11, 5 males n = 19, 7 males  
 (Mean ± SEM) p value 
Δ CD16 0.37 ± 1.76 -0.20 ± 1.62 0.81 
Δ TLR2 -13.57 ± 5.19 2.86 ± 6.74 0.06 
Δ TLR4 -11.11 ± 5.79 3.63 ± 2.97 0.04 
Δ CD11a -0.08 ± 2.18 1.36 ± 1.16 0.57 
Δ CD71 -2.47 ± 6.31 2.57 ± 4.04 0.51 
Δ CRP -0.12 ± 0.19 0.36 ± 0.25 0.14 
Δ LBP -0.13 ± 0.14 -0.30 ± 0.27 0.82 
Δ AGP 0.19 ± 0.10 -0.02 ± 0.06 0.10* 
Δ IL6 0.05 ± 0.24 -0.27 ± 0.21 0.85 
Δ TNF 0.00 ± 0.10 -0.23 ± 0.11 0.82* 
*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, 
toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.11. Effects of avocado consumption on markers of inflammation in participants who had an increase in the fecal relative 
abundance of the genus Lachnobacterium 
 Control Avocado Difference Between Groups 
 n = 9, 2 males n = 5, 2 males  
 (Mean ± SEM) p value 
Δ CD16 -1.46 ± 1.92 -0.91 ± 2.60 0.87 
Δ TLR2 -4.30 ± 5.12 5.34 ± 16.62 0.60 
Δ TLR4 -2.88 ± 4.42 9.99 ± 6.89 0.16 
Δ CD11a 2.15 ± 1.83 0.11 ± 0.10 0.88* 
Δ CD71 -10.47 ± 6.97 13.06 ± 16.53 0.26 
Δ CRP -0.76 ± 0.99 -0.07 ± 0.11 0.41* 
Δ LBP 0.36 ± 0.21 -1.50 ± 0.77 0.07 
Δ AGP 0.09 ± 0.14 0.12 ± 0.08 0.74* 
Δ IL6 -0.25 ± 0.45 -2.43 ± 2.35 0.41 
Δ TNF 0.03 ± 0.14 -0.20 ± 0.12 0.32 
*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, 
toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.12. Effects of avocado consumption on markers of inflammation in participants who had an increase in the fecal 
concentration of acetate. 




 n = 16, 7 males n = 23, 10 males  
 (Mean ± SEM) p value 
Δ CD16 1.77 ± 1.44 -1.17 ± 1.42 0.16 
Δ TLR2 -8.07 ± 6.56 -2.14 ± 5.37 0.49 
Δ TLR4 -7.13 ± 4.24 -2.03 ± 3.53 0.36 
Δ CD11a -0.03 ± 1.66 0.29 ± 2.29 0.66* 
Δ CD71 10.53 ± 7.03 0.08 ± 5.19 0.25 
Δ CRP -0.21 ± 0.54 0.11 ± 0.24 0.76* 
Δ LBP 0.28 ± 0.15 -0.17 ± 0.16 0.05 
Δ AGP 0.01 ± 0.13 -0.02 ± 0.06 0.84 
Δ IL6 -0.04 ± 0.29 -0.17 ± 0.17 0.70 
Δ TNF -0.11 ± 0.09 -0.07 ± 0.08 0.72 
*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, 
toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.13. Effects of avocado consumption on markers of inflammation in participants who had an increase in the sum of the fecal 
concentrations of short-chain fatty acids (acetate, propionate, and butyrate).  




 n = 17, 7 males n = 21, 9 males  
 (Mean ± SEM) p value 
Δ CD16 2.25 ± 1.24 -1.07 ± 1.53 0.10 
Δ TLR2 -6.63 ± 6.65 -1.76 ± 5.91 0.59 
Δ TLR4 -5.33 ± 4.09 -3.72 ± 3.66 0.77 
Δ CD11a -0.05 ± 1.66 0.32 ± 2.53 0.74* 
Δ CD71 10.48 ± 7.04 -0.78 ± 5.67 0.23 
Δ CRP -0.21 ± 0.51 -0.05 ± 0.20 0.70* 
Δ LBP 0.31 ± 0.13 -0.18 ± 0.17 0.03 
Δ AGP -0.01 ± 0.12 -0.02 ± 0.06 0.96 
Δ IL6 -0.11 ± 0.27 -0.09 ± 0.18 0.94 
Δ TNF -0.09 ± 0.10 -0.07 ± 0.09 0.88 
*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, 
toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.14. Effects of avocado consumption on markers of inflammation in participants who had a decrease in visceral fat mass.   




 n = 31, 12 males n = 26, 10 males  
 (Mean ± SEM) p value 
Δ CD16 0.98 ± 1.15 -0.62 ± 1.10 0.32 
Δ TLR2 -0.20 ± 4.65 0.10 ± 4.32 0.96 
Δ TLR4 -4.80 ± 3.67 0.05 ± 2.86 0.30 
Δ CD11a -0.36 ± 1.01 -0.29 ± 2.35 0.35* 
Δ CD71 -4.85 ± 5.01 8.13 ± 4.15 0.06 
Δ CRP -0.21 ± 0.32 0.05 ± 0.13 0.77* 
Δ LBP 0.12 ± 0.09 -1.02 ± 0.76 0.20* 
Δ AGP 0.06 ± 0.08 0.02 ± 0.05 0.69 
Δ IL6 0.10 ± 0.20 -0.63 ± 0.59 0.18* 
Δ TNF -0.05 ± 0.10 -0.15 ± 0.09 0.44 
*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, 
toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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Table 3.15. Effects of avocado consumption on markers of inflammation in participants who had a decrease in the ratio of visceral to 
subcutaneous fat mass.  




 n = 27, 11 males n = 25, 10 males  
 (Mean ± SEM) p value 
Δ CD16 0.37 ± 1.11 -0.96 ± 1.65 0.51 
Δ TLR2 1.22 ± 5.99 -3.45 ± 6.27 0.59 
Δ TLR4 -9.32 ± 4.64 0.23 ± 3.45 0.11 
Δ CD11a -0.31 ± 1.44 -2.15 ± 2.08 0.72* 
Δ CD71 -10.15 ± 7.14 1.44 ± 5.11 0.20 
Δ CRP -0.40 ± 0.38 -0.03 ± 0.12 0.69* 
Δ LBP -0.03 ± 0.09 -1.13 ± 0.83 0.48* 
Δ AGP 0.02 ± 0.10 0.04 ± 0.06 0.90 
Δ IL6 -0.16 ± 0.21 -0.75 ± 0.71 0.33* 
Δ TNF -0.18 ± 0.10 -0.14 ± 0.10 0.79 
*Group differences were tested using the Mann Whitney-Wilcoxon test for non-normally distributed variables; all other group 
comparisons were done using T-tests. SEM, standard error of mean; CRP, c-reactive protein; LBP, Lipopolysaccharide binding 
protein; AGP, alpha-1-acid glycoprotein; IL-6, interleukin-6; TNF, tumor necrosis factor; CD16, cluster of differentiation-16; TLR2, 
toll-like receptor 2; TLR4, toll-like receptor 4; CD11a, cluster of differentiation 11a; CD71, cluster of differentiation 71 
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CHAPTER 4: General Discussion and Conclusions 
 In summary, rates of obesity and its related comorbid conditions are increasing across the 
industrialized and quickly industrializing world. Although there exists a vast amount of research 
investigating the impact of obesity on individuals and communities, the need for dietary 
strategies for the prevention and treatment are great. A more detailed understanding of the 
interactions between diet, the GI microbiota, and inflammation and metabolic endotoxemia may 
inform these dietary strategies.  
 The Mediterranean diet pattern may be one such effective strategy for the treatment and 
prevention of obesity and metabolic disease. The efficacy of the Mediterranean diet pattern for 
promoting health is due in part to its focus on foods like fruits, vegetables, whole grains, 
legumes, and nuts which contain an abundance and variety of dietary fibers. In chapters 2 and 3 
of this thesis, the effects of dietary fiber on the structure and function of the GI microbiota were 
investigated in an adult population without diagnosed metabolic disease and of varying weight 
statuses both cross-sectionally (chapter 2) and as a dietary intervention (chapter 3). The 
investigation of inflammation in this population is lacking in the literature, with most 
investigations of metabolic endotoxemia being performed in older adults with advanced obesity 
and metabolic disease. Study of inflammation in this less metabolically-ill sample was difficult 
and may have contributed to null results in Chapter 3. 
 Although data analyses were often unable to detect relationships between diet and 
inflammation among the study participants, future interventions that aim to investigate metabolic 
endotoxemia in the general population are needed. Future studies may benefit from increased 
sample size, higher interventional doses, and the addition of more sensitive measures of 
inflammation and GI barrier function. 
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APPENDIX A: Blood Analysis 
1. Materials 
1.1. 15ml Conical Tubes 
1.2. 50ml Conical Tubes 
1.3. 1.5 ml Microcentrifuge Tubes 
1.4. 1.2ml Cryovials 
1.5. 1x Phosphate Buffered Saline (PBS) 
1.6. Ficoll HistoPaque (GE Life Sciences) 
1.7. 5ml Serological Pipettes 
1.8. 10ml Serological Pipettes  
1.9. Serological Pipetter 
1.9.1.  P200 Pipette and Filtered Pipette Tips 
1.9.2. P1000 Pipette and Filtered Pipette Tips 
1.9.3. Nalgene® Mr. Frosty Freezing Container 
1.9.4. 100% Isopropanol 
1.9.5. 4ml of Freezing Media (see below) 
1.9.5.1. Roswell Park Memorial Institute (RPMI) Media with L-tryptophan 
1.9.5.2. Dimethyl Sulfoxide (DMSO) 
1.9.5.3. Penicillin-Streptomycin (10,000 U/ml) (Pen-Strep) 
1.9.5.4. Fetal Bovine Serum (FBS) 
2. Procedure 
2.1. Preparation 
2.1.1. Prepare freezing media 
2.1.1.1. In a sterile 50ml conical tube, combine 37ml of RPMI, 7.5ml of FBS, 5ml 
DMSO, and 0.5ml of Pen-Strep for a total of 50ml. Gently mix. 
2.1.1.2. Pipette into 1ml aliquots and store at -20C for future use 
2.1.1.3. Mixture is considered within expiration until the soonest expiration of 
individual components  
2.1.2. Prepare Nalgene® Mr. Frosty freezing container as instructed in product manual, 
adding 100% propanol, and ensuring container is room temperature before use 
2.1.3. Pipette 3ml of Ficoll HistoPaque in each of 4 15ml microcentrifuge tubes 
2.2. Blood Draw: Obtain approximately 10ml of venous blood in both EDTA anti-coagulant-
coated tube 
2.3. Measure and Dilute Blood: Using a serological pipet, draw up blood from EDTA blood 
tube and note the volume. Dispense into the labeled 50ml conical tube. Add an equal 
amount of 1x PBS to create a 1:1 ratio. Gently mix with the serological pipet.  
2.4. Layering Step: Carefully layer (don’t mix) ¼ of the blood:PBS solution (about 4ml) over 
the ficoll. Start by dispensing 1 small drop of blood onto the side of the tube. Let this 
drop trail down to the PBS. This creates a path for the rest of the blood. Now slowly and 
carefully dispense the rest of the blood:PBS solution over the ficoll. 
2.5. Spin: Ensuring tubes stay upright, spin at 400 x g for 40 minutes at room temperature 
(22C) with the brake off.  
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2.6. Obtain Buffy Coat: When centrifuge is done, keeping the tubes upright, draw up the buff 
coat layer and place into 1 15ml tube (All tube buffy coats can go into one tube).  
2.7. Wash and Spin Buffy Coat: Add 6ml of 1x PBS and spin at 400 x g for 10 minutes at 
room temperature. Brake may be turned on or off. 
2.8. Aliquot Plasma: Collect the plasma from the top of the tube. This can be used for later 
analysis but note that it has been diluted 1:2 with PBS. 
2.9. Wash Again: When the buffy coat is done spinning, discard supernatant completely. Add 
6ml of 1x PBS, resuspend pellet at the bottom of the tube gently. Spin at 400 x g for 10 
minutes. Brake may be turned on or off. 
2.10. Resuspend in Freezing Medium: Discard supernatant completely. Carefully 
remove all the remaining excess PBS without disturbing the pellet. Resuspend cells into 
2 ml of freezing media. Add 1ml to each cryovial. Store in Nalgene® Mr. Frosty 
freezing container at -80. 
2.11. Storage: Cells should be stored for less than 1 week at -80. Transfer to liquid 




APPENDIX B: Flow Cytometry Sample Preparation 
1. Materials 
1.1. Separation Buffer (see procedure for instructions)  
1.1.1. MACS BSA Stock Solution (Miltenyi Biotec, Bergisch Gladbach, Germany) 
1.1.2. autoMACS Rinsing Solution (Miltenyi Biotec, Bergisch Gladbach, Germany) 
1.2. Fluorophore-conjugated Anti-Human Antibodies (Miltenyi Biotec, Bergisch Gladbach, 
Germany) 
1.2.1. DAPI-conjugated CD14 Antibody  
1.2.2. Am-Cyan-conjugated CD16 Antibody  
1.2.3. PE-Cy7-conguated TLR2 Antibody 
1.2.4. APC-conjuagted TLR4 Antibody 
1.2.5. FITC-conjugated CD11a Antibody 
1.2.6. PE-conjugated CD71 Antibody 
1.3. Roswell Park Memorial Institute (RPMI) Medium without L-tryptophan 
1.4. Serological Pipetter 
1.5. Serological Pipettes 
1.6. 15ml Conical Tubes 
1.7. Falcon Tubes 
1.8. 1.5ml Microcentrifuge Tubes 
2. Procedure 
2.1. Make separation buffer 
2.1.1. Make Separation Buffer” by diluting the MACS BSA Stock Solution 1:20 with 
the autoMACS Rinsing Solution. Keep cool (2-8C) until ready to use. 
2.2. Pre-cool centrifuge to 4C 
2.3. Thaw cells at 37-40C, shaking gently, until there is only a very small amount of ice left 
in the vial. 
2.4. Transfer cells to a 15ml tube and add 10ml of cool (4C) RPMI-1640, gently shake tube. 
2.5. Centrifuge at 200xG for 10min at 4C (1371 RPM with F-35-6-30 rotor). 
2.6. Remove supernatant completely 
2.7. Resuspend in 102 μl of separation buffer 
2.8. Gently vortex to ensure complete resuspension of cells. 
2.9. Perform cell count 
2.9.1. Add 2μl of cells to a microcentrifuge tube 
2.9.2. Add 198μl of trypan blue stain 
2.9.3. Moisten cover slip 
2.9.4. Pipette 10μl of stained cells to hemocytometer and count according to 
hemocytometer product manual or use an automatic cell counter 
2.10. Dilute cells  
2.10.1. Cells should be at a concentration of 10^6 for CD14 and CD71 staining and 10^7 
for CD16, TLR2, TLR4, and CD11a staining 
2.10.2. If you need to dilute cells by a factor of 10 
2.10.2.1. 100μl of cells remain after counting 
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2.10.2.2. Add 900 μl of separation buffer 
2.10.2.3. Mix gently by pipetting up and down 
2.10.2.4. Discard 900 μl of the cell mixture 
2.10.2.5. Cells have now been diluted by a factor of 10 
2.10.2.6. This may be repeated if cells must be further diluted 
2.11. If using only single-stained cells, see step 2.12. If preparing multi-stained cells, 
advance to step 2.13. 
2.12. Staining for single-stained cells  
2.12.1. CD14 – recommended for 10^6 
2.12.1.1. Remove 2 μl of cells 
2.12.1.2. Add 2 μl of CD14 and mix well 
2.12.1.3. Incubate for 10 minutes at 2-8C in the dark 
2.12.1.4. Add 2ml of separation buffer 
2.12.1.5. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.12.1.6. Remove supernatant completely 
2.12.1.7. Resuspend in 500μl separation buffer  
2.12.1.8. Transfer to filter-top falcon tube for flow cytometry analysis 
2.12.2. CD16 – recommended for 10^7 
2.12.2.1. Add 10 μl of CD16 and mix well 
2.12.2.2. Incubate for 10 in the dark at 2-8C in the dark 
2.12.2.3. Add 2mL of separation buffer 
2.12.2.4. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.12.2.5. Remove supernatant completely 
2.12.2.6. Resuspend in 500μl separation buffer  
2.12.2.7. Transfer to filter-top falcon tube for flow cytometry analysis 
2.12.3. CD282 – recommended for 10^7 
2.12.3.1. Add 10 μl of CD282 and mix well 
2.12.3.2. Incubate for 10 in the dark at 2-8C in the dark 
2.12.3.3. Add 2mL of separation buffer 
2.12.3.4. Centrifuge at 300xG for 10 minutes 
2.12.3.5. Remove supernatant completely 
2.12.3.6. Resuspend in 500μl separation buffer  
2.12.3.7. Transfer to filter-top falcon tube for flow cytometry analysis 
2.12.4. CD284 – recommended for 10^7 
2.12.4.1. Add 10 μl of CD284 and mix well 
2.12.4.2. Incubate for 10 in the dark at 2-8C in the dark 
2.12.4.3. Add 2mL of separation buffer 
2.12.4.4. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.12.4.5. Remove supernatant completely 
2.12.4.6. Resuspend in 500μl separation buffer  
2.12.4.7. Transfer to filter-top falcon tube for flow cytometry analysis 
2.12.5. CD11a – recommended for 10^7 
2.12.5.1. Add 10 μl of CD11a and mix well 
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2.12.5.2. Incubate for 10 in the dark at 2-8C in the dark 
2.12.5.3. Add 2mL of separation buffer 
2.12.5.4. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.12.5.5. Remove supernatant completely 
2.12.5.6. Resuspend in 500μl separation buffer  
2.12.5.7. Transfer to filter-top falcon tube for flow cytometry analysis 
2.12.6. CD71 – recommended for 10^6 
2.12.6.1. Remove 2 μl of cells 
2.12.6.2. Add 2 μl of CD71 and mix well 
2.12.6.3. Incubate for 10 minutes at 2-8C in the dark 
2.12.6.4. Add 2ml of separation buffer 
2.12.6.5. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.12.6.6. Remove supernatant completely 
2.12.6.7. Resuspend in 500μl separation buffer  
2.12.6.8. Transfer to filter-top falcon tube for flow cytometry analysis 
2.12.7. PI – recommended for 10^6 
2.12.7.1. Add 200μl of PI (1ug/dl) and mix well 
2.12.7.2. Incubate for 10 in the dark at 2-8C in the dark 
2.12.7.3. Add 2mL of separation buffer 
2.12.7.4. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.12.7.5. Remove supernatant completely 
2.12.7.6. Resuspend in 500μl separation buffer  
2.12.7.7. Transfer to filter-top falcon tube for flow cytometry analysis 
2.13. Staining for multi-stained cells 
2.13.1. Tubes used for multi-stained cell analysis are as follows 
2.13.1.1. Unlabeled 
2.13.1.2. All stains (excluding CD71) 
2.13.1.3. CD14 FMO 
2.13.1.4. CD16 FMO 
2.13.1.5. TLR2 FMO 
2.13.1.6. TLR4 FMO 
2.13.1.7. CD11a FMO 
2.13.1.8. CD71 with CD14 
2.13.2. Unlabeled tube 
2.13.2.1. Start preparation at step 2.1 and continue through step 2.6 
2.13.2.2. Resuspend in 500μl of separation buffer 
2.13.2.3. Cells are ready for flow cytometry analysis 
2.13.3. All stains (excluding CD71) tube 
2.13.3.1. Start preparation at step 2.1 and continue through step 2.10. For all stains 
tube, the final dilution should be 10^6 cells.  
2.13.3.2. Remove 6μl of cells, for a final volume of 94ul. 
2.13.3.3. Add 2μl of CD14 and 1μl of CD16, TLR2, TLR4, and CD11a for a final 
staining volume of 100ul.  
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2.13.3.4. Incubate for 10 in the dark at 2-8C in the dark 
2.13.3.5. Add 2mL of separation buffer 
2.13.3.6. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.13.3.7. Remove supernatant completely 
2.13.3.8. Resuspend in 300μl separation buffer  
2.13.3.9. Add 200μl of PI (1ug/dl) and mix well 
2.13.3.10. Transfer to filter-top falcon tube for flow cytometry analysis 
2.13.4. CD14 FMO tube 
2.13.4.1. Start preparation at step 2.1 and continue through step 2.10. For FMO 
tubes, the final dilution should be 10^6 cells.  
2.13.4.2. Remove 4μl of cells, for a final volume of 96ul. 
2.13.4.3. Add 1μl of CD16, TLR2, TLR4, and CD11a for a final staining volume of 
100ul.  
2.13.4.4. Incubate for 10 in the dark at 2-8C in the dark 
2.13.4.5. Add 2mL of separation buffer 
2.13.4.6. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.13.4.7. Remove supernatant completely 
2.13.4.8. Resuspend in 300μl separation buffer  
2.13.4.9. Add 200μl of PI (1ug/dl) and mix well 
2.13.4.10. Transfer to filter-top falcon tube for flow cytometry analysis 
2.13.5. CD16 FMO tube 
2.13.5.1. Start preparation at step 2.1 and continue through step 2.10. For FMO 
tubes, the final dilution should be 10^6 cells.  
2.13.5.2. Remove 5μl of cells, for a final volume of 95ul. 
2.13.5.3. Add 2μl of CD14 and 1μl of TLR2, TLR4, and CD11a for a final staining 
volume of 100ul.  
2.13.5.4. Incubate for 10 in the dark at 2-8C in the dark 
2.13.5.5. Add 2mL of separation buffer 
2.13.5.6. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.13.5.7. Remove supernatant completely 
2.13.5.8. Resuspend in 300μl separation buffer  
2.13.5.9. Add 200μl of PI (1ug/dl) and mix well 
2.13.5.10. Transfer to filter-top falcon tube for flow cytometry analysis 
2.13.6. TLR2 FMO tube 
2.13.6.1. Start preparation at step 2.1 and continue through step 2.10. For FMO 
tubes, the final dilution should be 10^6 cells.  
2.13.6.2. Remove 5μl of cells, for a final volume of 95ul. 
2.13.6.3. Add 2μl of CD14 and 1μl of CD16, TLR4, and CD11a for a final staining 
volume of 100ul.  
2.13.6.4. Incubate for 10 in the dark at 2-8C in the dark 
2.13.6.5. Add 2mL of separation buffer 
2.13.6.6. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.13.6.7. Remove supernatant completely 
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2.13.6.8. Resuspend in 300μl separation buffer  
2.13.6.9. Add 200μl of PI (1ug/dl) and mix well 
2.13.6.10. Transfer to filter-top falcon tube for flow cytometry analysis 
2.13.7. TLR4 FMO tube 
2.13.7.1. Start preparation at step 2.1 and continue through step 2.10. For FMO 
tubes, the final dilution should be 10^6 cells.  
2.13.7.2. Remove 5μl of cells, for a final volume of 95ul. 
2.13.7.3. Add 2μl of CD14 and 1μl of CD16, TLR2, and CD11a for a final staining 
volume of 100ul.  
2.13.7.4. Incubate for 10 in the dark at 2-8C in the dark 
2.13.7.5. Add 2mL of separation buffer 
2.13.7.6. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.13.7.7. Remove supernatant completely 
2.13.7.8. Resuspend in 300μl separation buffer  
2.13.7.9. Add 200μl of PI (1 μg/dl) and mix well 
2.13.7.10. Transfer to filter-top falcon tube for flow cytometry analysis 
2.13.8. CD11a FMO tube 
2.13.8.1. Start preparation at step 2.1 and continue through step 2.10. For FMO 
tubes, the final dilution should be 10^6 cells.  
2.13.8.2. Remove 5μl of cells, for a final volume of 95ul. 
2.13.8.3. Add 2μl of CD14 and 1 μl  of CD16, TLR2, and TLR4 for a final staining 
volume of 100ul.  
2.13.8.4. Incubate for 10 in the dark at 2-8C in the dark 
2.13.8.5. Add 2mL of separation buffer 
2.13.8.6. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.13.8.7. Remove supernatant completely 
2.13.8.8. Resuspend in 300μl separation buffer  
2.13.8.9. Add 200μl of PI (1 μg/dl) and mix well 
2.13.8.10. Transfer to filter-top falcon tube for flow cytometry analysis 
2.13.9. CD71 with CD14 tube 
2.13.9.1. Start preparation at step 2.1 and continue through step 2.10. The final 
dilution should be 10^6 cells.  
2.13.9.2. Remove 4μl of cells, for a final volume of 96ul. 
2.13.9.3. Add 2μl of CD14 and CD71 for a final staining volume of 100ul.  
2.13.9.4. Incubate for 10 in the dark at 2-8C in the dark 
2.13.9.5. Add 2mL of separation buffer 
2.13.9.6. Centrifuge at 300xG for 10 minutes (1679 RPM with F-35-6-30 rotor). 
2.13.9.7. Remove supernatant completely 
2.13.9.8. Resuspend in 300μl separation buffer  
2.13.9.9. Add 200μl of PI (1ug/dl) and mix well 
2.13.9.10. Transfer to filter-top falcon tube for flow cytometry analysis 
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APPENDIX C: Flow Cytometry Sample Analysis 
1. Materials 
1.1. Samples Prepared for Flow Cytometry Analysis 
1.2. BD LSR II Flow Cytometer 
1.3. BD FACSDiva Software 
2. Notes 
2.1. A full tutorial for use of the BD LSR II Flow Cytometer and BD FACSDiva software is 
outside the scope of this report, however, aspects of sample measurement will be shared. 
3. Gating: Threshold gates were set for the following: 
3.1. Discrimination of live from dead cells through gating for PI fluorescence  
3.2. Selection of events whose forward and side scatter indicate a likely identification as 
monocytes 
3.3. CD14-DAPI positive events confirming identification as monocytes  
3.4. Target event threshold was 10,000  
3.5. Storage gate was set to capture all events 
4. Voltage settings: 
4.1. Forward Scatter: 430 
4.2. Side Scatter: 340 
4.3. DAPI: 440 
4.4. AmCyan: 350 
4.5. PE-Cy7: 790 
4.6. APC: 580 
4.7. FITC: 470 
4.8. PE: 490 
4.9. PI: 550 
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APPENDIX D: Flow Cytometry Data Analysis 
1. Materials 
1.1. FCS Express Software or Similar 
1.2. Datafiles Obtained from BD LSR II Flow Cytometer or Similar 
2. Procedure 
2.1. Files per sample should include 
2.1.1. Unlabeled 
2.1.2. CD14 FMO 
2.1.3. CD16 FMO 
2.1.4. TLR2 FMO 
2.1.5. TLR4 FMO 
2.1.6. CD11a FMO 
2.1.7. CD71 with CD14 
2.2. Singlet-Doublet Discrimination: Doublet events are identified by a scatter plot of 
forward scatter height (FSC-H) to forward scatter area (FSC-A). 
 
2.3. Live-Dead Discrimination 
2.3.1. Load the datafile from the unlabeled control tube 
2.3.2. Apply singlet gate from step 2.2 
2.3.3. Set quadrant with 98% of cells in lower left-hand corner 
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2.3.4. Load the datafile from the all stained tube 
2.3.5. Set gate for cells which fall in lower and upper left-hand quadrants 
 
2.4. Monocyte Discrimination 
2.4.1. Apply live gate from step 2.3 
2.4.2. Load the datafile from the CD14 FMO tube 
2.4.3. Set quadrant with 98% of cells in lower left-hand corner 
2.4.4. Load the datafile from the all stained tube 
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2.4.5. Set gate for cells which fall in lower and upper right-hand quadrants 
 
2.5. Cell Marker Measurement (Using TLR2-PE-Cy7 as an example) 
2.5.1. Apply CD14 gate from step 2.4 
2.5.2. Load the datafile from the TLR2 FMO tube 
2.5.3. Set quadrant with 98% of cells in lower left-hand corner 
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2.5.4. Load the datafile from the all stained tube 
2.5.5. Sum percentage of cells in upper and lower right-hand quadrants for final 




2.6. Quality Threshold: For this report, a quality threshold of 1,000 events in the CD14 




APPENDIX E: Flow Cytometry Validation 
1. Determination of cell population 
1.1. It was the aim of the present study to investigate metabolic endotoxemia. Peripheral 
blood mononuclear cells (PBMC) were the subset of leukocytes collected. Because LPS 
is mainly targeted by members of the innate immune system, monocytes were chosen as 
a cellular target. The other main population of leukocytes captured as PBMCs (T cells) 
were excluded.  
2. Determination of cellular markers 
2.1. All cellular markers have been reported in the literature to be associated with poor diet 
quality, specifically increased saturated fat and decreased dietary fiber intake. 
2.2. CD14  
2.2.1. Cluster of differentiation 14 
2.2.2. Chosen as a monocyte marker for identification of this cellular population 
2.3. CD16 
2.3.1. Cluster of differentiation 16 
2.3.2. Chosen as a marker of monocyte maturity  
2.4. TLR2 
2.4.1. Toll-like receptor 2; cluster of differentiation 282 
2.4.2. Chosen due to its reception of gram-positive pathogen associated molecular 
patterns 
2.5. TLR4  
2.5.1. Toll-like receptor 4; cluster of differentiation 284 
2.5.2. Chosen due to its reception of gram-negative pathogen associated molecular 
patterns 
2.6. CD11a 
2.6.1. Cluster of differentiation 11a; Integrin alpha L 
2.6.2. Chosen as a measure of monocyte diapedesis, or the propensity of the circulating 
monocyte population to become tissue-resident macrophages 
2.7. CD71  
2.7.1. Cluster of differentiation 71; transferrin receptor protein 1 
2.7.2. Chosen to measure infection response 
3. Determination of flow cytometer 
3.1. Flow cytometry analysis was conducted at the Flow Cytometry Facility at the Roy J. 
Carver Center for Biotechnology at the University of Illinois at Urbana-Champaign. Of 
the machines available, the BD LSR II was chosen for its number of laser channels due 
to the size of our fluorochrome panel (7 stains). 
4. Building a fluorochrome panel 
4.1. In the building of a fluorochrome panel, the abundance of each monocyte marker was 
considered with the intent of pairing the brightest fluorochrome with the least abundant 
cellular marker. However, availability of fluorochrome-conjugated antibodies from the 
supplier limited this process somewhat. 
4.2. The supplier, Miltenyi Biotec (Bergische Gladbach, Germany), provided invaluable 
assistance in the design of this panel. This service is commonly available from 
companies who distribute flow cytometry products. 
5. Validation of cellular preparation 
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5.1. Cell counting 
5.1.1. A phase contrast hemocytometer (Hausser Scientific, Horsham, PA) was used to 
count cells for each participant sample.  
5.1.1.1. Instructions for using a hemocytometer for cell counting are widely 
available from many online sources 
5.1.1.2. Formula used for calculating cell count 
5.1.1.2.1. Mean live cells per hemocytometer quadrant * dilution factor of 
sample added to hemocytometer * volume of hemocytometer chamber * 
volume of sample remaining = cell count 
5.1.1.2.2. Volume of hemocytometer was calculated from the information 
sheet included with the product 
5.1.2. During validation, hemocytometer counts were verified by measurement using an 
automatic cell counter (Beckman-Coulter Z series; Bray, CA). After verification by 
automatic cell counter, it was discovered that concentrations determined by 
hemocytometer were incorrectly calculated and inflated by a factor of 1,000. This 
was due to the use of incorrect units in the calculation of the volume of the 
hemocytometer chamber. 
5.2. Testing of cell staining duration 
5.2.1. The manufacturer’s recommendation was to stain cells for 10 minutes at 4°C.  
5.2.2. To validate this staining time, one PBMC sample was split into 6 separate tubes. 
Cells were stained according to the procedure outlined in Appendix B. Two tubes 
were incubated for 5 minutes, two tubes for 10 minutes, and two tubes for 15 
minutes.  
5.2.3. 5 minutes of incubation resulted in a significant decrease in total events counted 
by the flow cytometer. No significant differences in events counted were found 
between 10 and 15 minutes of incubation. Thus 10 minutes was determined to be 
optimal for cell staining. 
6. Determination of flow cytometer parameters (gating and voltage) 
6.1. Gates and voltages were determined by employees of the Flow Cytometry Facility at the 
Roy J. Carver Center for Biotechnology at the University of Illinois at Urbana-
Champaign. 
7. Validation of multi-stain procedure  
7.1. Spectral overlap 
7.1.1. Spectral overlap is a concern whenever multiple fluorochromes are used. The 
Benton-Dickson FACSDiva software version 8.0.1 (Benton Dickinson Biosciences; 
San Jose, CA) is equipped with an automatic compensation tool that was used in 
this procedure. 
7.1.2. Compensation was unable to resolve the spectral overlap between FITC and PE, 
so these two stains were evaluated separately. 
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1.1. Successfully-validated ELISA kits 
1.1.1. C-reactive protein (CRP) 
1.1.1.1. Manufacturer: Invitrogen, Carlsbad, CA 
1.1.1.2. Product Number: BMS288INST 
1.1.2. Lipopolysaccharide-binding protein (LBP) 
1.1.2.1. Manufacturer: Hycult Biotech, Uden, The Netherlands 
1.1.2.2. Product Number: HK315 
1.1.3. Alpha-1-glycoprotein (AGP) 
1.1.3.1.1. Manufacturer: R&D Systems, Minneapolis, MN 
1.1.3.1.2. Product Number: DAGP00 
1.1.4. Interleukin (IL)-6 
1.1.4.1. Manufacturer: R&D Systems, Minneapolis, MN 
1.1.4.2. Product Number: HS600C 
1.1.5. Tumor necrosis factor (TNF) 
1.1.5.1. Manufacturer: Alpco, Salem, NH 
1.1.5.2. Product Number: 45-TNFHUU-E01 
1.2. ELISA kits that failed validation 
1.2.1. IL-6 
1.2.1.1. Manufacturer: Invitrogen, Carlsbad, CA 
1.2.1.2. Product Number: BMS213HS 
1.2.2. TNF  
1.2.2.1. Manufacturer: Invitrogen, Carlsbad, CA 
1.2.2.2. Product Number: BMS223HS 
2. Validations 
2.1. General 
2.1.1. Human plasma from blood collected in ethylenediaminetetraacetic acid (EDTA)-
coated tubes was used for the quantification of CRP, LBP, AGP, and IL-6. This 
plasma had previously diluted 1:1 with 1x phosphate buffered-saline during the 
isolation of peripheral mononuclear cells. Plasma was stored at -20°C between 
processing and aliquoting. Plasma was thawed on ice, aliquoted into smaller 
volumes, re-frozen at -20°C between aliquoting and assaying. Aliquoted plasma was 
thawed on ice and warmed to room temperature before assaying. 
2.1.2. Human plasma from blood collected in heparin-coated tubes was used for the 
quantification of TNF. This plasma was not diluted. Plasma was stored at -20°C 
between processing and aliquoting. Plasma was thawed on ice, aliquoted into 
smaller volumes, re-frozen at -20°C between aliquoting and assaying. Aliquoted 
plasma was thawed on ice and warmed to room temperature before assaying. 
2.1.3. A quality threshold was imposed for the standard curve. Plates with an R2 value 
less than 0.9 were repeated. 
2.1.4. A quality threshold was imposed for the coefficient of variation (CV). If the CV 
was greater than 20% for any sample (run in duplicate or triplicate), the sample was 
re-assayed. 
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2.2. Kits that failed validation 
2.2.1. The IL-6 and TNF ELISA kits purchased from Invitrogen failed validation due to 
sample concentrations too low for detection. Both the 1:2 diluted EDTA plasma and 
undiluted heparin plasma were used during validation, however concentrations were 
too low for detection in most participants samples. Validation was attempted 3 times 
with input from technical support with no success. 
2.3. Successfully validated kits 
2.3.1. CRP  
2.3.1.1. 1:2 diluted EDTA plasma was used. The protocol calls for a pre-dilution 
step of 1:500 with assay buffer included in the kit. This yielded plasma with a 
final dilution factor of 1:1000. 
2.3.1.2. Many samples had final calculated concentrations above or below the 
standard curve, so many samples were run repeatedly at dilutions of 1:250 
(final dilution factor 1:500) or 1:1000 (final dilution factor 1:2000).  
2.3.2. LBP 
2.3.2.1.  1:2 diluted EDTA plasma was used. The protocol calls for a pre-dilution 
step of 1:1000 with wash buffer included in the kit. This yielded plasma with a 
final dilution factor of 1:2000. 
2.3.2.2. Many samples had final calculated concentrations above or below the 
standard curve, so many samples were run repeatedly at dilutions of 1:250 
(final dilution factor 1:500), 1:500 (final dilution factor 1:1000), or 1:1000 
(final dilution factor 1:2000). 
2.3.3. AGP 
2.3.3.1. 1:2 diluted EDTA plasma was used. The protocol calls for a pre-dilution 
step of 1:10000 with calibrator diluent included in the kit. This yielded plasma 
with a final dilution factor of 1:20000. 
2.3.3.2. No other dilutions were necessary to capture participant concentrations on 
the standard curve. 
2.3.4. IL-6 
2.3.4.1. 1:2 diluted EDTA plasma was used. No pre-dilutions were recommended 
in the protocol. 
2.3.4.2. No samples required additional dilution to fit the standard curve, however 
some concentrations of participant samples were too low for detection. 
2.3.5. TNF 
2.3.5.1. Undiluted heparin plasma was used. No pre-dilutions were recommended 
in the protocol. 
2.3.5.2. No samples required additional dilution to fit the standard curve, however 
some concentrations of participant samples were too low for detection. 
 
